{"doc_id": "si-2022-0099-reg-1", "parent_doc_id": "si-2022-0099", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "1. These Regulations may be cited as the European Union (Clinical Trials", "text_raw": "1. These Regulations may be cited as the European Union (Clinical Trials \n\non Medicinal Products for Human Use) (Principal) Regulations 2022.", "text_norm": "1 regulation may cited european union (clinical trial medicinal product human use) (principal) regulation 2022", "start_char": 665, "end_char": 809, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-2", "parent_doc_id": "si-2022-0099", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "text_raw": "2. (1) These Regulations apply to all clinical trials conducted in the State. \n\n(2) These Regulations do not apply to non-interventional studies. \n\nInterpretation", "text_norm": "2 (1) regulation apply clinical trial conducted state (2) regulation apply non-interventional study interpretation", "start_char": 809, "end_char": 974, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-3", "parent_doc_id": "si-2022-0099", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "(1) In these Regulations—", "text_raw": "3. \n\n(1) In these Regulations— \n\n“Advisory Committee for Human Medicines” means the committee established \nby section 9 of the Irish Medicines Board Act 1995 (No. 29 of 1995), as \namended; \n\n“Agency” means the European Medicines Agency, established by Regulation \n(EC) No. 726/2004 of the European Parliament and of the Council of 31 March \n20042; \n\n“Assessment Report” means the report required to be drawn up by the reporting \nMember State or the Member State concerned, as appropriate, in the context of \nan application for a clinical trial under Article 6(2) and Article 7(2) of the \nClinical Trials Regulation. \n\n“Authority” means the Health Products Regulatory Authority established by \nsection 3 of the Irish Medicines Board Act 1995 (No. 29 of 1995), as amended; \n\n“Clinical Trials Regulation” means Regulation (EU) No. 536/2014 of the \nEuropean Parliament and of the Council of 16 April 20141 on clinical trials on \nmedicinal products for human use; \n\n1 O.J. No. L 158, 27.5.2014, p. 1. \n2 O.J. No. L 136, 30.4.2004, p. 1. \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 4th March, 2022. \n\n \n \n \n \n \n \n \n \n \n\f[99] 3 \n\n“Commission Delegated Regulation (EU) 2017/1569” means Commission \nDelegated Regulation (EU) 2017/1569 of 23 May 20173; \n\n“clinical study” has the same meaning as it has in the Clinical Trials Regulation; \n\n“clinical trial” has the same meaning as it has in the Clinical Trials Regulation; \n\n“Data Protection Acts 1988 to 2018” means the Data Protection Act 1988 (No. \n25 of 1988), the Data Protection Act 2003 (No. 6 of 2003) and the Data \nProtection Act 2018 (No. 7 of 2018); \n\n“Declaration of Helsinki” means the Declaration of Helsinki adopted by the \nGeneral Assembly of the World Medical Association in June 1964, and as \namended by the General Assembly of that Association from time to time; \n\n“Directive” means Directive 2001/20/EC of the European Parliament and of the \nCouncil of 4 April 20014; \n“Directive 2001/83/EC6” means Directive 2001/83/EC of the European \nParliament and of the Council; \n\n“EU database” means the database established under Article 81 of the Clinical \nTrials Regulation; \n\n“EU portal” means the electronic portal established under Article 80 of the \nClinical Trials Regulation; \n\n“EudraGMDP database” means the EU database, maintained and operated by \nthe European Medicines Agency, on manufacturing, import and wholesaledistribution authorisations, and good manufacturing-practice (GMP) and gooddistribution-practice (GDP) certificates; \n\n“General Data Protection Regulation” means Regulation (EU) 2016/679 of the \nEuropean Parliament and of the Council of 27 April 20165; \n\n“incapacitated subject” means a subject who is, for reasons other than the age of \nlegal competence to give informed consent, incapable of giving informed \nconsent to participate in a clinical trial; \n\n“investigator” for the purposes of Article 49 of the Clinical Trials Regulation \nand these Regulations means - \n\n(a) \n\n(b) \n\n(c) \n\na medical practitioner within the meaning of section 2 of the \nMedical Practitioners Act 2007 (No. 25 of 2007), \n\na visiting EEA practitioner within the meaning of section 2 of the \nMedical Practitioners Act 2007, or \n\na registered dentist within the meaning of section 2 of the Dentists \nAct 1985 (No. 9 of 1985); \n\n“Joint Controllership Arrangement” means the arrangement agreed by the \nEuropean Commission, European Medicines Agency, Member States, sponsors \n\n3 O.J. No. L 238, 16.9.2017, p. 12. \n4 O.J. No. L 121, 1.5.2001, p. 34. \n5 O.J. No. L 119, 4.5.2016, p. 1. \n6 O.J. No. L 311, 28.11.2001, p. 67 \n\n \n \n\f4 [99] \n\nand marketing authorisation applicants or holders for the purpose of processing \npersonal data captured in the EU portal; \n\n“legally designated representative”, for the purposes of these Regulations and \nthe Clinical Trials Regulation only, means— \n\n(a) \n\nin relation to an incapacitated subject who is, or is being \nconsidered as, a subject for a clinical trial— \n\n(i) \n\na person, other than a person connected with the conduct of \nthe trial, who by virtue of his or her family or other personal \nrelationship with the individual— \n\n(aa) can provide the best interpretation of the will and \ntheir \n\nindividual based on \n\nthe \n\npreferences of \nknowledge of the individual, \n\n(bb) is available and willing to act for that purpose, or \n\n(ii) \n\nif there is no such person, the medical practitioner primarily \nresponsible for the medical treatment provided to the \nindividual where he or she— \n\n(aa) can provide the best interpretation of the will and \ntheir \n\nindividual based on \n\npreferences of \nknowledge of the individual, \n\nthe \n\n(bb) is not involved in the conduct of the trial, \n\n(cc) \n\nis of the view that participation in the trial will not \nprejudice the health and wellbeing of the individual, \nand \n\n(dd) is available and willing to act for that purpose, and \n\n(b) \n\nin relation to a minor who is, or is being considered as, a subject \nfor a clinical trial, a guardian within the meaning of the \nGuardianship of Infants Act 1964 (No. 7 of 1964); \n\n“legal representative” means the natural or legal person established in the \nEuropean Union as the legal representative of a clinical trial sponsor who is not \nestablished in the Union; \n\n“manufacturer’s authorisation” means an authorisation for the manufacture or \nimport of investigational medicinal products referred to in Article 61(1) of the \nClinical Trials Regulation which is for the time being in force and which has \nbeen granted by the Authority pursuant to Regulation 38; \n\n“marketing authorisation” means an authorisation which is for the time being in \nforce and which has been granted by the Authority under the Medicinal Products \n(Control of Placing on the Market) Regulations 2007 (S.I. No. 540 of 2007), or \nby the Commission under Regulation (EC) No. 726/20042and includes a \nmarketing authorisation issued by the competent authority of an EEA State, other \nthan the State, in accordance with Directive 2001/83/EC6; \n\n“medical doctor” for the purpose of Article 49 of the Clinical Trials Regulation \nmeans a registered medical practitioner; \n\n \n \n\f[99] 5 \n\n“Minister” means the Minister for Health; \n\n“minor” means a person under the age of 16 years; \n\n“National Office” has the meaning assigned to it by Regulation 5 of the European \nUnion Clinical Trials on Medicinal Products for Human Use) (National Research \nEthics Committees) Regulations 2022 (S.I. No. 41 of 2022); \n\n“National Research Ethics Committee” has the meaning assigned to it by \nRegulation 13 of the European Union (Clinical Trials on Medicinal Products for \nHuman Use) (National Research Ethics Committees) Regulations 2022 (S.I. No. \n41 of 2022); \n\n“nominated ethics committee” means the National Research Ethics Committee \nnominated by the National Office to assess and provide an opinion on a specific \nclinical trial application, or substantial modification to a clinical trial granted \nauthorisation, pursuant to the Clinical Trials Regulation; \n\n“non-commercial sponsor” means a sponsor who has no commercial or financial \ninterest in the outcome of the clinical trial; \n\n“non-commercial clinical trial\" means a clinical trial conducted by a noncommercial sponsor which fulfils the following characteristics— \n\n(a) \n\n(b) \n\nthe ownership of the investigation data belongs to the noncommercial sponsor from the inception of the clinical trial, and \n\nthe design, conduct, recruitment, recording of data and reporting \nof the results of the investigation remain under the control of the \nnon-commercial sponsor; \n\n“Part I” refers to Part I of the Assessment Report; \n\n“Part II” refers to Part II of the Assessment Report; \n\n“premises” means any place (physical or virtual), ship or other vessel, aircraft, \nrailway wagon or other vehicle or other mobile facility, other than a dwelling, \nand includes a container used to transport an investigational medicinal product \nand/or an auxiliary medicinal product or other relevant thing; \n\n“qualified person” means a person with the qualifications and experience \nspecified in Article 49(2) and (3) of Directive 2001/83/EC6 and named in the \nmanufacturer’s authorisation as being responsible for the functions set out in \nArticle 62 of the Clinical Trials Regulation; \n\n“relevant health care provider” means – \n\n(a) \n\nin relation to a person receiving services in pursuance of the \nHealth Acts 1947 to 2007— \n\n(i) \n\n(ii) \n\nin a case where a health service body is providing the health \ncare, that body, or \n\nin any other case, the health service body which entered the \narrangements under which the health care is provided, or \n\n(b) \n\nin relation to any other person receiving health care, the person \nprimarily responsible for providing that health care; \n\n \n\f6 [99] \n\n“registered nurse” means a person registered in the Register of Nurses and \nMidwives established under section 46(1)(a) of the Nurses and Midwives Act \n2011 (No. 41 of 2011); \n\n“registered pharmacist” means a person registered in the Register of Pharmacists \nestablished under section 13(1) of the Pharmacy Act 2007 (No. 20 of 2007); \n\n“Register of Exemptions” means the register of processes specified in Article \n61(6) of the Clinical Trials Regulation which are exempt from the requirements \nof Article 61(1) and which is established under Regulation 30 herein; \n“Regulation (EC) No 726/20042” means regulations of the European Parliament \nand of the Council of 31 March 2004; \n“Regulation (EU) 2017/5567” means Commission Implementing Regulation \n(EU) 2017/556 of 24 March 2017; \n\n“reporting Member State” means the Member State concerned appointed as \nreporting Member State under Article 5 of the Clinical Trials Regulation; \n\n“subject” means an individual who participates in a clinical trial, either as a \nrecipient of an investigational medicinal product or as a control; \n\n“S.I. No. 40 of 2022” means the European Union (Clinical Trials on Medicinal \nProducts for Human Use) Regulations 2022; \n\n“S.I. No. 41 of 2022” means the European Union (Clinical Trials on Medicinal \nProducts for Human Use) (National Research Ethics Committees) Regulations \n2022; \n\n(2) A word or expression which is used in these Regulations and which is \nalso used in the Clinical Trials Regulation has, unless the context otherwise \nrequires, the same meaning in these Regulations as it has in the Clinical Trials \nRegulation. \n\nRoles of Authority, National Office and Nominated Ethics Committee", "text_norm": "3 (1) regulations-- advisory committee human medicine mean committee established section 9 irish medicine board act 1995 (no 29 1995) amended agency mean european medicine agency established regulation (ec) no 726 2004 european parliament council 31 march 20042 assessment report mean report required drawn reporting member state member state concerned appropriate context application clinical trial article 6(2) article 7(2) clinical trial regulation authority mean health product regulatory authority established section 3 irish medicine board act 1995 (no 29 1995) amended clinical trial regulation mean regulation (eu) no 536 2014 european parliament council 16 april 20141 clinical trial medicinal product human use 1 o.j no l 158 27.5.2014 p 1 2 o.j no l 136 30.4.2004 p 1 notice making statutory instrument published iris oifigiuil 4th march 2022 99 3 commission delegated regulation (eu) 2017 1569 mean commission delegated regulation (eu) 2017 1569 23 may 20173 clinical study meaning clinical trial regulation clinical trial meaning clinical trial regulation data protection act 1988 2018 mean data protection act 1988 (no 25 1988) data protection act 2003 (no 6 2003) data protection act 2018 (no 7 2018) declaration helsinki mean declaration helsinki adopted general assembly world medical association june 1964 amended general assembly association time time directive mean directive 2001 20 ec european parliament council 4 april 20014 directive 2001 83 ec6 mean directive 2001 83 ec european parliament council eu database mean database established article 81 clinical trial regulation eu portal mean electronic portal established article 80 clinical trial regulation eudragmdp database mean eu database maintained operated european medicine agency manufacturing import wholesaledistribution authorisation good manufacturing-practice (gmp) gooddistribution-practice (gdp) certificate general data protection regulation mean regulation (eu) 2016 679 european parliament council 27 april 20165 incapacitated subject mean subject reason age legal competence give informed consent incapable giving informed consent participate clinical trial investigator purpose article 49 clinical trial regulation regulation mean - (a) (b) (c) medical practitioner within meaning section 2 medical practitioner act 2007 (no 25 2007) visiting eea practitioner within meaning section 2 medical practitioner act 2007 registered dentist within meaning section 2 dentist act 1985 (no 9 1985) joint controllership arrangement mean arrangement agreed european commission european medicine agency member state sponsor 3 o.j no l 238 16.9.2017 p 12 4 o.j no l 121 1.5.2001 p 34 5 o.j no l 119 4.5.2016 p 1 6 o.j no l 311 28.11.2001 p 67 4 99 marketing authorisation applicant holder purpose processing personal data captured eu portal legally designated representative purpose regulation clinical trial regulation means-- (a) relation incapacitated subject considered subject clinical trial-- (i) person person connected conduct trial virtue family personal relationship individual-- (aa) provide best interpretation individual based preference knowledge individual (bb) available willing act purpose (ii) person medical practitioner primarily responsible medical treatment provided individual she-- (aa) provide best interpretation individual based preference knowledge individual (bb) involved conduct trial (cc) view participation trial prejudice health wellbeing individual (dd) available willing act purpose (b) relation minor considered subject clinical trial guardian within meaning guardianship infant act 1964 (no 7 1964) legal representative mean natural legal person established european union legal representative clinical trial sponsor established union manufacturer authorisation mean authorisation manufacture import investigational medicinal product referred article 61(1) clinical trial regulation time force granted authority pursuant regulation 38 marketing authorisation mean authorisation time force granted authority medicinal product (control placing market) regulation 2007 (s.i no 540 2007) commission regulation (ec) no 726 20042and includes marketing authorisation issued competent authority eea state state accordance directive 2001 83 ec6 medical doctor purpose article 49 clinical trial regulation mean registered medical practitioner 99 5 minister mean minister health minor mean person age 16 year national office meaning assigned regulation 5 european union clinical trial medicinal product human use) (national research ethic committees) regulation 2022 (s.i no 41 2022) national research ethic committee meaning assigned regulation 13 european union (clinical trial medicinal product human use) (national research ethic committees) regulation 2022 (s.i no 41 2022) nominated ethic committee mean national research ethic committee nominated national office ass provide opinion specific clinical trial application substantial modification clinical trial granted authorisation pursuant clinical trial regulation non-commercial sponsor mean sponsor commercial financial interest outcome clinical trial non-commercial clinical trial mean clinical trial conducted noncommercial sponsor fulfils following characteristics-- (a) (b) ownership investigation data belongs noncommercial sponsor inception clinical trial design conduct recruitment recording data reporting result investigation remain control non-commercial sponsor part refers part assessment report part ii refers part ii assessment report premise mean place (physical virtual) ship vessel aircraft railway wagon vehicle mobile facility dwelling includes container used transport investigational medicinal product auxiliary medicinal product relevant thing qualified person mean person qualification experience specified article 49(2) (3) directive 2001 83 ec6 named manufacturer authorisation responsible function set article 62 clinical trial regulation relevant health care provider mean - (a) relation person receiving service pursuance health act 1947 2007-- (i) (ii) case health service body providing health care body case health service body entered arrangement health care provided (b) relation person receiving health care person primarily responsible providing health care 6 99 registered nurse mean person registered register nurse midwife established section 46(1)(a) nurse midwife act 2011 (no 41 2011) registered pharmacist mean person registered register pharmacist established section 13(1) pharmacy act 2007 (no 20 2007) register exemption mean register process specified article 61(6) clinical trial regulation exempt requirement article 61(1) established regulation 30 herein regulation (ec) 726 20042 mean regulation european parliament council 31 march 2004 regulation (eu) 2017 5567 mean commission implementing regulation (eu) 2017 556 24 march 2017 reporting member state mean member state concerned appointed reporting member state article 5 clinical trial regulation subject mean individual participates clinical trial either recipient investigational medicinal product control s.i no 40 2022 mean european union (clinical trial medicinal product human use) regulation 2022 s.i no 41 2022 mean european union (clinical trial medicinal product human use) (national research ethic committees) regulation 2022 (2) word expression used regulation also used clinical trial regulation unless context otherwise requires meaning regulation clinical trial regulation role authority national office nominated ethic committee", "start_char": 974, "end_char": 11455, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-4", "parent_doc_id": "si-2022-0099", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "4. (1) Save as may be otherwise expressly provided for in these Regulations", "text_raw": "4. (1) Save as may be otherwise expressly provided for in these Regulations \n\nand subject to paragraph (2)— \n\n(a) \n\nthe role of Member State, pursuant to the Clinical Trials \nRegulation, shall be carried out by the Authority and the National \nOffice in conjunction with the nominated ethics committee, each \nof which— \n\n(i) may communicate information when carrying out their \nrespective functions under the Clinical Trials Regulation, \nand \n\n(ii) \n\nshall keep such communications confidential, \n\n(b) where the State is the reporting Member State under the Clinical \nTrials Regulation, the Authority and the National Office in \nconjunction with the nominated ethics committee shall coordinate in the review of applications for the conduct of clinical \n\n7 O.J. No. L 80, 25.3.2017, p. 7. \n\n \n \n \n\f[99] 7 \n\ntrials and applications for substantial modifications to clinical \ntrials granted authorisation, and perform the functions ascribed to \nthe reporting Member State under the Clinical Trials Regulation \nwithin the timelines set out therein, \n\n(c) where the State is a Member State concerned under the Clinical \nTrials Regulation, the Authority and the National Office in \nconjunction with the nominated ethics committee shall perform \nthe functions ascribed to the Member State concerned under the \nClinical Trials Regulation within the timelines set out therein, \n\n(d) where the State is an additional Member State concerned pursuant \nto Article 14 of the Clinical Trials Regulation, the Authority and \nthe National Office in conjunction with the nominated ethics \ncommittee shall perform the functions ascribed to additional \nMember States concerned under the Clinical Trials Regulation \nwithin the timelines set out therein, and \n\n(e) \n\nnotifications to the EU portal envisaged at Article 80 of the \nClinical Trials Regulation and submissions to the EU database \nenvisaged at Article 81 thereof shall be made by either the \nAuthority or the National Office, as appropriate. \n\n(f) \n\nthe Authority shall— \n\n(i) \n\nperform the scientific review referred to in Article 4 of the \nClinical Trials Regulation, \n\n(ii) validate the aspects covered by the Part I assessment, \npursuant to Chapters II and III of the Clinical Trials \nRegulation, \n\n(iii) be the national contact point for the purposes of Article 83 \n\nof the Clinical Trials Regulation, \n\n(iv) perform the inspections envisaged by Articles 63 and 78 of \n\nthe Clinical Trials Regulation, \n\n(v) \n\ncollect the fees envisaged by Chapter XVI of the Clinical \nTrials Regulation, \n\n(vi) be responsible for the enforcement of these Regulations and \n\nthe prosecution of any offences thereunder. \n\n(g) \n\nthe National Office, in conjunction with the nominated ethics \ncommittee, shall— \n\n(i) \n\nperform the ethical review referred to in Article 4 of the \nClinical Trials Regulation, \n\n(ii) validate the aspects covered by the Part II assessment, \npursuant to Chapters II and III of the Clinical Trials \nRegulation. \n\nthe National Office shall have the additional functions described \nin S.I. No. 41 of 2022. \n\na National Research Ethics Committee shall have the additional \nfunctions described in S.I. No. 41 of 2022. \n\n(h) \n\n(i) \n\n \n \n \n\f8 [99] \n\n(2) The Minister may publish guidelines as to the appropriate division of \ntasks prescribed by the Clinical Trials Regulation, between the Authority, the \nNational Office and the nominated ethics committee, as appropriate. \n\nPART 2 \n\nAUTHORISATION TO CONDUCT CLINICAL TRIALS AND \nAUTHORISATION OF SUBSTANTIAL MODIFICATIONS TO CLINICAL \nTRIALS GRANTED AUTHORISATION \n\nDetermination on role as a reporting Member State", "text_norm": "4 (1) save may otherwise expressly provided regulation subject paragraph (2)-- (a) role member state pursuant clinical trial regulation shall carried authority national office conjunction nominated ethic committee which-- (i) may communicate information carrying respective function clinical trial regulation (ii) shall keep communication confidential (b) state reporting member state clinical trial regulation authority national office conjunction nominated ethic committee shall coordinate review application conduct clinical 7 o.j no l 80 25.3.2017 p 7 99 7 trial application substantial modification clinical trial granted authorisation perform function ascribed reporting member state clinical trial regulation within timeline set therein (c) state member state concerned clinical trial regulation authority national office conjunction nominated ethic committee shall perform function ascribed member state concerned clinical trial regulation within timeline set therein (d) state additional member state concerned pursuant article 14 clinical trial regulation authority national office conjunction nominated ethic committee shall perform function ascribed additional member state concerned clinical trial regulation within timeline set therein (e) notification eu portal envisaged article 80 clinical trial regulation submission eu database envisaged article 81 thereof shall made either authority national office appropriate (f) authority shall-- (i) perform scientific review referred article 4 clinical trial regulation (ii) validate aspect covered part assessment pursuant chapter ii iii clinical trial regulation (iii) national contact point purpose article 83 clinical trial regulation (iv) perform inspection envisaged article 63 78 clinical trial regulation (v) collect fee envisaged chapter xvi clinical trial regulation (vi) responsible enforcement regulation prosecution offence thereunder (g) national office conjunction nominated ethic committee shall-- (i) perform ethical review referred article 4 clinical trial regulation (ii) validate aspect covered part ii assessment pursuant chapter ii iii clinical trial regulation national office shall additional function described s.i no 41 2022 national research ethic committee shall additional function described s.i no 41 2022 (h) (i) 8 99 (2) minister may publish guideline appropriate division task prescribed clinical trial regulation authority national office nominated ethic committee appropriate part 2 authorisation conduct clinical trial authorisation substantial modification clinical trial granted authorisation determination role reporting member state", "start_char": 11455, "end_char": 15068, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-5", "parent_doc_id": "si-2022-0099", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "5. (1) Subject to paragraph (2), the Authority shall determine whether the", "text_raw": "5. (1) Subject to paragraph (2), the Authority shall determine whether the \nState is willing to be the reporting Member State pursuant to Article 5(1) of the \nClinical Trials Regulation, or not, and shall notify any decision to all Member \nStates concerned through the EU Portal. \n\n(2) Before making its determination under paragraph (1), the Authority shall \n\nconsult with the National Office. \n\nDetermination on scope of application", "text_norm": "5 (1) subject paragraph (2) authority shall determine whether state willing reporting member state pursuant article 5(1) clinical trial regulation shall notify decision member state concerned eu portal (2) making determination paragraph (1) authority shall consult national office determination scope application", "start_char": 15068, "end_char": 15505, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-6", "parent_doc_id": "si-2022-0099", "section_id": "reg-6", "section_label": "Regulation 6.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "6. The Authority shall assess whether the application for authorisation is", "text_raw": "6. The Authority shall assess whether the application for authorisation is \nwithin the scope of the Clinical Trials Regulation as envisaged by Article 5(3)(a) \nthereof. \n\nDrafting of Reports", "text_norm": "6 authority shall ass whether application authorisation within scope clinical trial regulation envisaged article 5(3)(a) thereof drafting report", "start_char": 15505, "end_char": 15698, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-7", "parent_doc_id": "si-2022-0099", "section_id": "reg-7", "section_label": "Regulation 7.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "7. Subject to the requirements of Regulations 8, 9, and 12, the Authority", "text_raw": "7. Subject to the requirements of Regulations 8, 9, and 12, the Authority \nshall draft Part I of the Assessment Report, and the National Office in \nconjunction with the nominated ethics committee shall draft Part II of the \nAssessment Report, and they shall coordinate with each other, as appropriate, to \nensure the production of the final Report. \n\nAssessment of application – Part I of Assessment Report", "text_norm": "7 subject requirement regulation 8 9 12 authority shall draft part assessment report national office conjunction nominated ethic committee shall draft part ii assessment report shall coordinate appropriate ensure production final report assessment application - part assessment report", "start_char": 15698, "end_char": 16107, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-8", "parent_doc_id": "si-2022-0099", "section_id": "reg-8", "section_label": "Regulation 8.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "8. (1) Subject to paragraph (2), the Authority shall—", "text_raw": "8. (1) Subject to paragraph (2), the Authority shall— \n\n(a) \n\nreview the application in terms of the scientific aspects covered \nby Part I of the Assessment Report, \n\n(b) draw up Part I of the Assessment Report under Article 6(2) of the \n\nClinical Trials Regulation, and \n\n(c) \n\nconclude on the application insofar as Part I of the Assessment \nReport is concerned, under Article 6(4) of the Clinical Trials \nRegulation. \n\n(2) In order to assist the Authority in the performance of its functions under \n\nparagraph (1)(b) and (1)(c), the nominated ethics committee shall— \n\n \n \n \n \n \n \n \n\f[99] 9 \n\n(a) \n\nreview the application in terms of the ethical aspects of the \nmatters covered by Part I of the Assessment Report, and \n\n(b) provide input to the Authority on those ethical aspects, in \n\naccordance with Regulation 19 of S.I. No. 41 of 2022. \n\nAssessment of application – Part II of Assessment Report", "text_norm": "8 (1) subject paragraph (2) authority shall-- (a) review application term scientific aspect covered part assessment report (b) draw part assessment report article 6(2) clinical trial regulation (c) conclude application insofar part assessment report concerned article 6(4) clinical trial regulation (2) order assist authority performance function paragraph (1)(b) (1)(c) nominated ethic committee shall-- 99 9 (a) review application term ethical aspect matter covered part assessment report (b) provide input authority ethical aspect accordance regulation 19 s.i no 41 2022 assessment application - part ii assessment report", "start_char": 16107, "end_char": 17011, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-9", "parent_doc_id": "si-2022-0099", "section_id": "reg-9", "section_label": "Regulation 9.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "9. The National Office and the nominated ethics committee shall—", "text_raw": "9. The National Office and the nominated ethics committee shall— \n\n(1) review the application in terms of the matters covered by Part II of the \n\nAssessment Report, \n\n(2) draw up part II of the Assessment Report under Article 7(1) of the \n\nClinical Trials Regulation in accordance with Regulation 7, and \n\n(3) conclude on Part II of the Assessment Report under Article 7(2) of the \n\nClinical Trials Regulation. \n\nGrant or refusal of application", "text_norm": "9 national office nominated ethic committee shall-- (1) review application term matter covered part ii assessment report (2) draw part ii assessment report article 7(1) clinical trial regulation accordance regulation 7 (3) conclude part ii assessment report article 7(2) clinical trial regulation grant refusal application", "start_char": 17011, "end_char": 17458, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-10", "parent_doc_id": "si-2022-0099", "section_id": "reg-10", "section_label": "Regulation 10.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "10. (1) In accordance with Article 8(1) or Article 14(3) of the Clinical Trials", "text_raw": "10. (1) In accordance with Article 8(1) or Article 14(3) of the Clinical Trials \nRegulation, as appropriate, the Authority shall issue an administrative single \ndecision, through the EU portal, as to whether— \n\n(a) \n\n(b) \n\n(c) \n\na clinical trial is authorised, \n\na clinical trial is authorised subject to certain conditions, or \n\nauthorisation of a clinical trial is refused. \n\n(2) Authorisation of a clinical trial shall be refused pursuant to Article 8(4) \n\nor Article 14(10) of the Clinical Trials Regulation, as appropriate, where— \n\n(a) \n\nthe Authority or the nominated ethics committee disagrees with \nthe reporting Member State’s conclusion as regards Part I of the \nAssessment Report on any of the grounds stated in the second \nsubparagraph of Article 8(2) or Article 14(4) of the Clinical Trials \nRegulation, as appropriate, \n\n(b) \n\nthe nominated ethics committee finds on duly justified grounds, \nthat the aspects addressed in Part II of the Assessment Report are \nnot complied with, or \n\n(c) \n\nthe nominated ethics committee has issued a negative opinion in \nrelation to the application. \n\nValidation of application for authorisation of a substantial modification", "text_norm": "10 (1) accordance article 8(1) article 14(3) clinical trial regulation appropriate authority shall issue administrative single decision eu portal whether-- (a) (b) (c) clinical trial authorised clinical trial authorised subject certain condition authorisation clinical trial refused (2) authorisation clinical trial shall refused pursuant article 8(4) article 14(10) clinical trial regulation appropriate where-- (a) authority nominated ethic committee disagrees reporting member state conclusion regard part assessment report ground stated second subparagraph article 8(2) article 14(4) clinical trial regulation appropriate (b) nominated ethic committee find duly justified ground aspect addressed part ii assessment report complied (c) nominated ethic committee issued negative opinion relation application validation application authorisation substantial modification", "start_char": 17458, "end_char": 18635, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-11", "parent_doc_id": "si-2022-0099", "section_id": "reg-11", "section_label": "Regulation 11.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "11. (1) The Authority shall validate the application for a substantial", "text_raw": "11. (1) The Authority shall validate the application for a substantial \nmodification and notify the sponsor of the matters at Article 17(2)(a) and (b) of \nthe Clinical Trials Regulation, where the substantial modification concerns— \n\n(a) \n\nan aspect covered by Part I of the Assessment Report as envisaged \nby Article 17 of the Clinical Trials Regulation, or \n\n \n \n \n \n\f10 [99] \n\n(b) \n\naspects covered by Parts I and II of the Assessment Report, as \nenvisaged by Article 21 of the Clinical Trials Regulation. \n\n(2) The National Office in conjunction with the nominated ethics committee \nshall validate the application and notify the sponsor of the matters at Article \n20(1)(a) and (b) of the Clinical Trials Regulation, where the substantial \nmodification concerns an aspect covered by Part II of the Assessment Report. \n\nAssessment of application for authorisation of a substantial modification", "text_norm": "11 (1) authority shall validate application substantial modification notify sponsor matter article 17(2)(a) (b) clinical trial regulation substantial modification concerns-- (a) aspect covered part assessment report envisaged article 17 clinical trial regulation 10 99 (b) aspect covered part ii assessment report envisaged article 21 clinical trial regulation (2) national office conjunction nominated ethic committee shall validate application notify sponsor matter article 20(1)(a) (b) clinical trial regulation substantial modification concern aspect covered part ii assessment report assessment application authorisation substantial modification", "start_char": 18635, "end_char": 19533, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-12", "parent_doc_id": "si-2022-0099", "section_id": "reg-12", "section_label": "Regulation 12.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "12. The following procedure shall apply in relation to the assessment of an", "text_raw": "12. The following procedure shall apply in relation to the assessment of an \n\napplication for authorisation of a substantial modification— \n\n(1) the Authority shall perform the scientific review of the Part I assessment \nin accordance with Articles 18 and 21, as appropriate, of the Clinical Trials \nRegulation, \n\n(2) in order for the Authority to conclude on the Part I assessment, the \nNational Office, in conjunction with the nominated ethics committee, shall \nprovide an opinion following ethical review of Part I, pursuant to Article 18 or \n21 of the Clinical Trials Regulation and Regulation 19 of S.I. No. 41 of 2022; \n\n(3) the Authority shall conclude on the Part I assessment in accordance with \n\nArticle 19 or 23 of the Clinical Trials Regulation, as appropriate, \n\n(4) the nominated ethics committee shall review and conclude on the Part II \nassessment in accordance with Article 20 or Article 23 of the Clinical Trials \nRegulation, as appropriate, \n\n(5) the Authority shall submit an administrative single decision on a \nsubstantial modification application for authorisation, in accordance with \nArticles 19 or 23 of the Clinical Trials Regulation, \n\n(6) the National Office shall submit an administrative single decision on a \nsubstantial modification application for authorisation in accordance with Article \n20 of the Clinical Trials Regulation. \n\nGrant or refusal of application for authorisation of a substantial modification", "text_norm": "12 following procedure shall apply relation assessment application authorisation substantial modification-- (1) authority shall perform scientific review part assessment accordance article 18 21 appropriate clinical trial regulation (2) order authority conclude part assessment national office conjunction nominated ethic committee shall provide opinion following ethical review part pursuant article 18 21 clinical trial regulation regulation 19 s.i no 41 2022 (3) authority shall conclude part assessment accordance article 19 23 clinical trial regulation appropriate (4) nominated ethic committee shall review conclude part ii assessment accordance article 20 article 23 clinical trial regulation appropriate (5) authority shall submit administrative single decision substantial modification application authorisation accordance article 19 23 clinical trial regulation (6) national office shall submit administrative single decision substantial modification application authorisation accordance article 20 clinical trial regulation grant refusal application authorisation substantial modification", "start_char": 19533, "end_char": 20979, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-13", "parent_doc_id": "si-2022-0099", "section_id": "reg-13", "section_label": "Regulation 13.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "13. (1) In accordance with Article 19(1) of the Clinical Trials Regulation", "text_raw": "13. (1) In accordance with Article 19(1) of the Clinical Trials Regulation \nand where the substantial modification concerns an aspect covered by Part I of \nthe Assessment Report, the Authority shall notify the sponsor through the EU \nportal as to whether— \n\n(a) \n\n(b) \n\nthe substantial modification is authorised, \n\nthe substantial modification is authorised subject to certain \nconditions, \n\n(c) \n\nauthorisation of the substantial modification is refused. \n\n(2) In accordance with Article 20(5) of the Clinical Trials Regulation and \nwhere the substantial modification concerns an aspect covered by Part II of the \nAssessment Report, the National Office (through the Authority if required by the \noperation of the EU portal) shall notify the sponsor through the EU portal as to \nwhether— \n\n \n \n \n\f[99] 11 \n\n(a) \n\n(b) \n\nthe substantial modification is authorised, \n\nthe substantial modification is authorised subject to conditions \nallowable under Article 20(5) of the Clinical Trials Regulation, \n\n(c) \n\nauthorisation of the substantial modification is refused. \n\n(3) In accordance with Article 23(1) of the Clinical Trials Regulation and \nwhere the modification concerns an aspect covered by Parts I and II of the \nAssessment Report, the National Office will co-ordinate with the Authority to \nensure that the sponsor is notified of the nominated ethics committee’s decision \nunder Article 22 of the Clinical Trials Regulation, to facilitate notification in \naccordance with a method prescribed under Article 20(5) of the Clinical Trials \nRegulation \n\n(4) Authorisation of a substantial modification of an aspect covered by Part \nI of the Assessment Report shall be refused pursuant to Article 19(2), where— \n\n(a) \n\nthe Authority or the nominated ethics committee disagrees with \nthe reporting Member State’s conclusions as regards Part I of the \nAssessment Report, on any of the grounds stated in the second \nsubparagraph of Article 19(2) of the of the Clinical Trials \nRegulation, or, \n\n(b) \n\nthe nominated ethics committee has issued a negative opinion in \nrelation to the substantial modification, \n\n(5) Authorisation of a substantial modification of an aspect covered by Part \nII of the Assessment Report shall be refused pursuant to Article 20(7) of the \nClinical Trials Regulation, where— \n\n(a) \n\n(b) \n\nthe nominated ethics committee finds that aspects covered by Part \nII of the Assessment Report are not complied with, or \n\nthe nominated ethics committee has issued a negative opinion in \naccordance with Article 20(7) of the Clinical Trials Regulation. \n\n(6) Authorisation of a substantial modification of an aspect covered by Part \n\nI and Part II of the Assessment Report shall be refused where— \n\n(a) \n\n(b) \n\nthe Authority or nominated ethics committee disagrees with the \nreporting Member State’s conclusions as regards Part I of the \nAssessment Report, on any of the grounds stated in the second \nsubparagraph of Article 23(2) of the Clinical Trials Regulation, \n\nthe nominated ethics committee finds, on duly justified grounds, \nthat the aspects covered by Part II of the Assessment Report are \nnot complied with, or \n\n(c) \n\nthe nominated ethics committee has issued a negative opinion in \nrelation to the substantial modification. \n\n \n \n \n\f12 [99] \n\nPART 3 \n\nCONDUCT OF CLINICAL TRIALS \n\nConduct of clinical trials within the State", "text_norm": "13 (1) accordance article 19(1) clinical trial regulation substantial modification concern aspect covered part assessment report authority shall notify sponsor eu portal whether-- (a) (b) substantial modification authorised substantial modification authorised subject certain condition (c) authorisation substantial modification refused (2) accordance article 20(5) clinical trial regulation substantial modification concern aspect covered part ii assessment report national office (through authority required operation eu portal) shall notify sponsor eu portal whether-- 99 11 (a) (b) substantial modification authorised substantial modification authorised subject condition allowable article 20(5) clinical trial regulation (c) authorisation substantial modification refused (3) accordance article 23(1) clinical trial regulation modification concern aspect covered part ii assessment report national office co-ordinate authority ensure sponsor notified nominated ethic committee decision article 22 clinical trial regulation facilitate notification accordance method prescribed article 20(5) clinical trial regulation (4) authorisation substantial modification aspect covered part assessment report shall refused pursuant article 19(2) where-- (a) authority nominated ethic committee disagrees reporting member state conclusion regard part assessment report ground stated second subparagraph article 19(2) clinical trial regulation (b) nominated ethic committee issued negative opinion relation substantial modification (5) authorisation substantial modification aspect covered part ii assessment report shall refused pursuant article 20(7) clinical trial regulation where-- (a) (b) nominated ethic committee find aspect covered part ii assessment report complied nominated ethic committee issued negative opinion accordance article 20(7) clinical trial regulation (6) authorisation substantial modification aspect covered part part ii assessment report shall refused where-- (a) (b) authority nominated ethic committee disagrees reporting member state conclusion regard part assessment report ground stated second subparagraph article 23(2) clinical trial regulation nominated ethic committee find duly justified ground aspect covered part ii assessment report complied (c) nominated ethic committee issued negative opinion relation substantial modification 12 99 part 3 conduct clinical trial conduct clinical trial within state", "start_char": 20979, "end_char": 24331, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-14", "parent_doc_id": "si-2022-0099", "section_id": "reg-14", "section_label": "Regulation 14.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "14. (1) Without prejudice to the Clinical Trials Regulation, a person shall", "text_raw": "14. (1) Without prejudice to the Clinical Trials Regulation, a person shall \n\nnot— \n\n(a) \n\nconduct a clinical trial, \n\n(b) perform the functions of the sponsor of a clinical trial (whether \nthat person is the sponsor or is acting under arrangements made \nwith that sponsor), or \n\n(c) \n\nperform the functions of the investigator of a clinical trial, \n\nin the State, otherwise than in accordance with paragraph (2). \n\n(2) The activities at paragraph 1(a) to (c) shall be conducted in accordance \n\nwith— \n\n(a) \n\n(b) \n(c) \n(d) \n\nthe Clinical Trials Regulation, \n\nthese Regulations, \nthe Declaration of Helsinki, \nthe authorisation to conduct that clinical trial as notified to the \nsponsor under Regulation 10 or 13 of these Regulations, \n\n(e) any clinical trial protocol relating to a particular clinical trial, \n\n(f) any particulars or documents, other than the clinical trial protocol, \naccompanying a clinical trial application, as may be modified \nfrom time to time in accordance with Articles 17 to 23 of the \nClinical Trials Regulation, \nthe conditions and principles of good clinical practice, and \nany other relevant guidance, including guidance published by the \nAgency or the European Commission. \n\n(g) \n(h) \n\nCompliance with obligations where the sponsor is not established in European \n\nUnion", "text_norm": "14 (1) without prejudice clinical trial regulation person shall not-- (a) conduct clinical trial (b) perform function sponsor clinical trial (whether person sponsor acting arrangement made sponsor) (c) perform function investigator clinical trial state otherwise accordance paragraph (2) (2) activity paragraph 1(a) (c) shall conducted accordance with-- (a) (b) (c) (d) clinical trial regulation regulation declaration helsinki authorisation conduct clinical trial notified sponsor regulation 10 13 regulation (e) clinical trial protocol relating particular clinical trial (f) particular document clinical trial protocol accompanying clinical trial application may modified time time accordance article 17 23 clinical trial regulation condition principle good clinical practice relevant guidance including guidance published agency european commission (g) (h) compliance obligation sponsor established european union", "start_char": 24331, "end_char": 25635, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-15", "parent_doc_id": "si-2022-0099", "section_id": "reg-15", "section_label": "Regulation 15.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "15. Where a natural or legal person is established in the European Union as", "text_raw": "15. Where a natural or legal person is established in the European Union as \nthe legal representative of a sponsor not established in the Union in \naccordance with Article 74(1) of the Clinical Trials Regulation, that \nrepresentative shall be responsible for ensuring compliance with the \nsponsor's obligations in the State, pursuant to the Clinical Trials \nRegulation and these Regulations. \n\nCharges to subjects of clinical trials", "text_norm": "15 natural legal person established european union legal representative sponsor established union accordance article 74(1) clinical trial regulation representative shall responsible ensuring compliance sponsor obligation state pursuant clinical trial regulation regulation charge subject clinical trial", "start_char": 25635, "end_char": 26070, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-16", "parent_doc_id": "si-2022-0099", "section_id": "reg-16", "section_label": "Regulation 16.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "16. (1) Subject to paragraph (2) and for the purposes of Article 92 of the", "text_raw": "16. (1) Subject to paragraph (2) and for the purposes of Article 92 of the \n\nClinical Trials Regulation, the sponsor of a clinical trial shall ensure that— \n\n(a) \n\nany investigational medicinal products or auxiliary medicinal \nproducts used in the clinical trial, and \n\n \n \n \n \n\f[99] 13 \n\n(b) \n\nany medical devices used for the administration of such products, \n\nare made available free of charge to the subject of the clinical trial. \n\n(2) Paragraph (1) shall not apply to a non-commercial clinical trial \nconducted by a non-commercial sponsor, except in circumstances where the \nsponsor has obtained the products or devices referred to in paragraph (1) free of \ncharge, in which case clinical trial subjects shall not bear any cost relating to \nsuch products or devices. \n\nDamage compensation", "text_norm": "16 (1) subject paragraph (2) purpose article 92 clinical trial regulation sponsor clinical trial shall ensure that-- (a) investigational medicinal product auxiliary medicinal product used clinical trial 99 13 (b) medical device used administration product made available free charge subject clinical trial (2) paragraph (1) shall apply non-commercial clinical trial conducted non-commercial sponsor except circumstance sponsor obtained product device referred paragraph (1) free charge case clinical trial subject shall bear cost relating product device damage compensation", "start_char": 26070, "end_char": 26867, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-17", "parent_doc_id": "si-2022-0099", "section_id": "reg-17", "section_label": "Regulation 17.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "17. A clinical trial shall not be authorised under these Regulations, or", "text_raw": "17. A clinical trial shall not be authorised under these Regulations, or \nconducted in the State, unless there is in place a policy of insurance or indemnity \nscheme to provide compensation for any damage suffered by a subject resulting \nfrom participation in the clinical trial, which policy or scheme shall be \nappropriate to the nature and the extent of the risk. \n\nPART 4 \n\nPROTECTION OF CLINICAL TRIAL SUBJECTS AND INFORMED \nCONSENT \n\nGeneral rules, emergency rules", "text_norm": "17 clinical trial shall authorised regulation conducted state unless place policy insurance indemnity scheme provide compensation damage suffered subject resulting participation clinical trial policy scheme shall appropriate nature extent risk part 4 protection clinical trial subject informed consent general rule emergency rule", "start_char": 26867, "end_char": 27340, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-18", "parent_doc_id": "si-2022-0099", "section_id": "reg-18", "section_label": "Regulation 18.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "18. (1) Subject to paragraph (3), a clinical trial shall not be conducted in the", "text_raw": "18. (1) Subject to paragraph (3), a clinical trial shall not be conducted in the \nState other than in accordance with the general rules laid down in Article 28 of \nthe Clinical Trials Regulation. \n\n(2) For the purposes of Article 28(1)(d), national law in relation to privacy \nand data rights of individuals shall also apply, in particular the Data Protection \nActs 1988 to 2018. \n\n(3) Article 28(1)(b) and (c), Article 31(1)(a) and (b), and Article 32(1)(a) \nand (b) of the Clinical Trials Regulation may be derogated from in emergency \nsituations in the manner prescribed by Article 35 of the Clinical Trials \nRegulation. \n\nInformed consent, consent in cluster trials", "text_norm": "18 (1) subject paragraph (3) clinical trial shall conducted state accordance general rule laid article 28 clinical trial regulation (2) purpose article 28(1)(d) national law relation privacy data right individual shall also apply particular data protection act 1988 2018 (3) article 28(1)(b) (c) article 31(1)(a) (b) article 32(1)(a) (b) clinical trial regulation may derogated emergency situation manner prescribed article 35 clinical trial regulation informed consent consent cluster trial", "start_char": 27340, "end_char": 28012, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-19", "parent_doc_id": "si-2022-0099", "section_id": "reg-19", "section_label": "Regulation 19.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "19. (1) For clinical trials in the State, informed consent shall be given or", "text_raw": "19. (1) For clinical trials in the State, informed consent shall be given or \n\nobtained in accordance with Article 29 of the Clinical Trials Regulation. \n\n(2) For clinical trials in the State, the interview prescribed by Article 29(2)(c) \nof the Clinical Trials Regulation shall be conducted by the investigator or by— \n\n(a) \n\n(b) \n\n(c) \n\na registered medical practitioner, \n\na registered dentist, or \n\na registered nurse \n\n \n \n \n \n \n\f14 [99] \n\nwhose training, experience and qualifications have been assessed by the \ninvestigator and determined to be appropriate to qualify him, or her, to \nconduct the interview. \n\n(3) For the purposes of Article 29(8) of the Clinical Trials Regulation, in \naddition to the informed consent given by a guardian, a minor who is capable of \nforming an opinion and assessing the information given to him or her, shall also \nassent in order to participate in a clinical trial. \n\n(4) For clinical trials which are to be conducted exclusively in the State, the \ninvestigator may obtain informed consent by simplified means, in accordance \nwith Article 30 of the Clinical Trials Regulation, provided all conditions therein \nare met. \n\nPART 5 \n\nCLINICAL TRIAL MASTER FILE AND ARCHIVING \n\nTrial master file", "text_norm": "19 (1) clinical trial state informed consent shall given obtained accordance article 29 clinical trial regulation (2) clinical trial state interview prescribed article 29(2)(c) clinical trial regulation shall conducted investigator by-- (a) (b) (c) registered medical practitioner registered dentist registered nurse 14 99 whose training experience qualification assessed investigator determined appropriate qualify conduct interview (3) purpose article 29(8) clinical trial regulation addition informed consent given guardian minor capable forming opinion assessing information given shall also assent order participate clinical trial (4) clinical trial conducted exclusively state investigator may obtain informed consent simplified mean accordance article 30 clinical trial regulation provided condition therein met part 5 clinical trial master file archiving trial master file", "start_char": 28012, "end_char": 29248, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-20", "parent_doc_id": "si-2022-0099", "section_id": "reg-20", "section_label": "Regulation 20.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "20. Without prejudice", "text_raw": "20. Without prejudice \n\nthe general obligations on sponsors and \ninvestigators under Article 57 of the Clinical Trials Regulation in relation to the \nkeeping of a clinical trial master file, the clinical trial master file shall— \n\nto \n\n(1) contain information— \n\n(a) \n\nsufficient to demonstrate whether the principles and guidelines of \ngood clinical practice, Annex I and, where applicable, Annex II \nto the Clinical Trials Regulation, have been complied with, and \n\n(b) which is specific to each phase of the clinical trial, \n\n(2) be readily available for inspection by the Authority and directly \n\naccessible upon request, and \n\n(3) form the basis for the Authority’s inspection as envisaged by Article 78 \n\nof the Clinical Trials Regulation. \n\nArchiving", "text_norm": "20 without prejudice general obligation sponsor investigator article 57 clinical trial regulation relation keeping clinical trial master file clinical trial master file shall-- (1) contain information-- (a) sufficient demonstrate whether principle guideline good clinical practice annex applicable annex ii clinical trial regulation complied (b) specific phase clinical trial (2) readily available inspection authority directly accessible upon request (3) form basis authority inspection envisaged article 78 clinical trial regulation archiving", "start_char": 29248, "end_char": 30008, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-21", "parent_doc_id": "si-2022-0099", "section_id": "reg-21", "section_label": "Regulation 21.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "21. Without prejudice", "text_raw": "21. Without prejudice \n\nthe general obligations on sponsors and \ninvestigators under Article 58 of the Clinical Trials Regulation in relation to \narchiving— \n\nto \n\n(1) the clinical trial master file shall be archived— \n\n(a) \n\nfor at least 25 years after the end of a clinical trial, or such longer \nperiod as may be agreed between the sponsor and investigator, \nand \n\n(b) \n\nin a manner which ensures that it can be made available for \ninspection by the Authority. \n\n \n \n \n \n \n \n\f(2) the medical files of trial subjects shall be retained for the maximum \nperiod of time permitted or required by the hospital, entity, or private practice at \nwhich the trial is conducted. \n\n[99] 15 \n\nPART 6 \n\nSUPERVISION AND CONTROL \n\nInspections in the State", "text_norm": "21 without prejudice general obligation sponsor investigator article 58 clinical trial regulation relation archiving-- (1) clinical trial master file shall archived-- (a) least 25 year end clinical trial longer period may agreed sponsor investigator (b) manner ensures made available inspection authority (2) medical file trial subject shall retained maximum period time permitted required hospital entity private practice trial conducted 99 15 part 6 supervision control inspection state", "start_char": 30008, "end_char": 30752, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-22", "parent_doc_id": "si-2022-0099", "section_id": "reg-22", "section_label": "Regulation 22.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "22. The Authority and the National Office in conjunction with the nominated", "text_raw": "22. The Authority and the National Office in conjunction with the nominated \nethics committee shall supervise clinical trials authorised for conduct in the \nState, and may communicate with each other in regard to same. All such \ncommunications shall be confidential.", "text_norm": "22 authority national office conjunction nominated ethic committee shall supervise clinical trial authorised conduct state may communicate regard same communication shall confidential", "start_char": 30752, "end_char": 31021, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-23", "parent_doc_id": "si-2022-0099", "section_id": "reg-23", "section_label": "Regulation 23.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "23. The Authority is designated as the competent authority for inspections", "text_raw": "23. The Authority is designated as the competent authority for inspections \npursuant to Article 78 of the Clinical Trials Regulation and shall carry out the \nfunctions of the competent authority in that regard. \n\nCorrective measures", "text_norm": "23 authority designated competent authority inspection pursuant article 78 clinical trial regulation shall carry function competent authority regard corrective measure", "start_char": 31021, "end_char": 31256, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-24", "parent_doc_id": "si-2022-0099", "section_id": "reg-24", "section_label": "Regulation 24.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "24. (1) Subject to paragraphs (3) and (4), where the State is a Member State", "text_raw": "24. (1) Subject to paragraphs (3) and (4), where the State is a Member State \nconcerned and the Authority has justified grounds for considering that the \nrequirements set out in the Clinical Trials Regulation are no longer met, the \nAuthority may take any corrective measure set out under Article 77(1) of the \nClinical Trials Regulation, in accordance with the procedure set out therein. \n\n(2) Any corrective measure taken by the Authority under paragraph (1) shall \nbe notified by the Authority to the sponsor or investigator and shall specify the \ndate on which the measure shall take effect. \n\n(3) Before the Authority takes a measure under Article 77(1) of the Clinical \nTrials Regulation, it shall, except where immediate action is required, ask the \nsponsor or the investigator for their opinion, which opinion shall be delivered \nwithin 7 days. \n\n(4) When considering whether the requirements of the Clinical Trials \n\nRegulation continue to be met, the Authority may consult with— \n\n(a) \n\n(b) \n\n(c) \n\nthe National Office, or \n\nthe nominated ethics committee, or \n\nother Member States concerned, \n\nbefore taking any of the measures referred to in Article 77(1) of the Clinical \nTrials Regulation. \n\n(5) Where a measure is taken by the Authority under Article 77(1) of the \nClinical Trials Regulation and paragraph (1) of this Regulation, the Authority \nshall immediately inform all Member States concerned through the EU portal, \nin accordance with Article 77(3) of the Clinical Trials Regulation. \n\n \n \n \n \n \n \n \n\f16 [99] \n\nPART 7 \nSAFETY REPORTING", "text_norm": "24 (1) subject paragraph (3) (4) state member state concerned authority justified ground considering requirement set clinical trial regulation longer met authority may take corrective measure set article 77(1) clinical trial regulation accordance procedure set therein (2) corrective measure taken authority paragraph (1) shall notified authority sponsor investigator shall specify date measure shall take effect (3) authority take measure article 77(1) clinical trial regulation shall except immediate action required ask sponsor investigator opinion opinion shall delivered within 7 day (4) considering whether requirement clinical trial regulation continue met authority may consult with-- (a) (b) (c) national office nominated ethic committee member state concerned taking measure referred article 77(1) clinical trial regulation (5) measure taken authority article 77(1) clinical trial regulation paragraph (1) regulation authority shall immediately inform member state concerned eu portal accordance article 77(3) clinical trial regulation 16 99 part 7 safety reporting", "start_char": 31256, "end_char": 32815, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-25", "parent_doc_id": "si-2022-0099", "section_id": "reg-25", "section_label": "Regulation 25.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "25. For clinical trials in the State—", "text_raw": "25. For clinical trials in the State— \n\n(1) investigators and sponsors shall comply with the reporting obligations to \nwhich they are subject under Articles 41, 42, and 43 of the Clinical Trials \nRegulation, \n\n(2) the Authority may, by way of notification, require the sponsor to send it \nthe records referred to in Article 41(3) of the Clinical Trials Regulation, or copies \nthereof.", "text_norm": "25 clinical trial state-- (1) investigator sponsor shall comply reporting obligation subject article 41 42 43 clinical trial regulation (2) authority may way notification require sponsor send record referred article 41(3) clinical trial regulation copy thereof", "start_char": 32815, "end_char": 33202, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-26", "parent_doc_id": "si-2022-0099", "section_id": "reg-26", "section_label": "Regulation 26.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "26. For the purposes of Article 44(2) and (3) of the Clinical Trials", "text_raw": "26. For the purposes of Article 44(2) and (3) of the Clinical Trials \n\nRegulation, the Authority— \n\n(1) shall cooperate with other Member States concerned in assessing the \ninformation reported under Articles 42 and 43 of the Clinical Trials Regulation, \nand \n\n(2) may consult with the National Office or the nominated ethics committee \n\nin the performance of its obligations under paragraph (1).", "text_norm": "26 purpose article 44(2) (3) clinical trial regulation authority-- (1) shall cooperate member state concerned assessing information reported article 42 43 clinical trial regulation (2) may consult national office nominated ethic committee performance obligation paragraph (1)", "start_char": 33202, "end_char": 33601, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-27", "parent_doc_id": "si-2022-0099", "section_id": "reg-27", "section_label": "Regulation 27.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "27. Without prejudice to the obligations on safety reporting under Chapter", "text_raw": "27. Without prejudice to the obligations on safety reporting under Chapter \nVII of the Clinical Trials Regulation, the sponsor shall maintain records of all \nadverse events and serious adverse events relating to a clinical trial which are \nreported by the investigators for that trial. \n\nMANUFACTURING AND IMPORTATION OF MEDICINAL PRODUCTS \nUSED IN CLINICAL TRIALS \n\nPART 8", "text_norm": "27 without prejudice obligation safety reporting chapter vii clinical trial regulation sponsor shall maintain record adverse event serious adverse event relating clinical trial reported investigator trial manufacturing importation medicinal product used clinical trial part 8", "start_char": 33601, "end_char": 33977, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-28", "parent_doc_id": "si-2022-0099", "section_id": "reg-28", "section_label": "Regulation 28.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "28. In accordance with Article 61(1) of the Clinical Trials Regulation, the", "text_raw": "28. In accordance with Article 61(1) of the Clinical Trials Regulation, the \nmanufacturing and importation of investigational medicinal products shall be \nsubject to the holding of a manufacturer’s authorisation. \n\nExemptions, Register of Exemptions", "text_norm": "28 accordance article 61(1) clinical trial regulation manufacturing importation investigational medicinal product shall subject holding manufacturer authorisation exemption register exemption", "start_char": 33977, "end_char": 34229, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-29", "parent_doc_id": "si-2022-0099", "section_id": "reg-29", "section_label": "Regulation 29.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "29. (1) For the purposes of Article 61(5) of the Clinical Trials Regulation,", "text_raw": "29. (1) For the purposes of Article 61(5) of the Clinical Trials Regulation, \nsetting out the conditions on which an exemption to the holding of an \nauthorisation may apply— \n\n(a) \n\n(b) \n\n“pharmacists” means “registered pharmacist” as defined in \nRegulation 3(1) of these Regulations, \n\n“other persons legally authorised in the Member State concerned” \nmeans a registered medical practitioner, or a registered dentist, as \ndefined in Regulation 3(1) of these Regulations, and \n\n(c) \n\na “clinic” includes a retail pharmacy business as defined in the \nPharmacy Act 2007 (No. 20 of 2007). \n\n \n \n \n \n \n \n \n \n \n\f[99] 17", "text_norm": "29 (1) purpose article 61(5) clinical trial regulation setting condition exemption holding authorisation may apply-- (a) (b) pharmacist mean registered pharmacist defined regulation 3(1) regulation person legally authorised member state concerned mean registered medical practitioner registered dentist defined regulation 3(1) regulation (c) clinic includes retail pharmacy business defined pharmacy act 2007 (no 20 2007) 99 17", "start_char": 34229, "end_char": 34846, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-30", "parent_doc_id": "si-2022-0099", "section_id": "reg-30", "section_label": "Regulation 30.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "30. (1) For the purposes of ensuring safety and reliability and robustness of", "text_raw": "30. (1) For the purposes of ensuring safety and reliability and robustness of \nthe data generated in the clinical trial as required by Article 61(6) of the Clinical \nTrials Regulation, the Authority— \n\n(a) \n\n(b) \n\nshall maintain a register of processes specified in Article 61(5) of \nthe Clinical Trials Regulation that are undertaken in hospitals, \nclinics and health centres that are exempt from the requirements \nof Article 61(1) of the Clinical Trials Regulation, defined as \n“Register of Exemptions” in Regulation 3(1), and \n\nthe Minister may publish guidelines prescribing further \nappropriate and proportionate requirements as may be required to \nensure the objectives of Article 61(6) of the Clinical Trials \nRegulation are met.", "text_norm": "30 (1) purpose ensuring safety reliability robustness data generated clinical trial required article 61(6) clinical trial regulation authority-- (a) (b) shall maintain register process specified article 61(5) clinical trial regulation undertaken hospital clinic health centre exempt requirement article 61(1) clinical trial regulation defined register exemption regulation 3(1) minister may publish guideline prescribing appropriate proportionate requirement may required ensure objective article 61(6) clinical trial regulation met", "start_char": 34846, "end_char": 35585, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-31", "parent_doc_id": "si-2022-0099", "section_id": "reg-31", "section_label": "Regulation 31.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "31. (1) Subject to paragraph (2), processes specified in Article 61(5) of the", "text_raw": "31. (1) Subject to paragraph (2), processes specified in Article 61(5) of the \nClinical Trials Regulation shall not be carried out unless they have been included \non the Register of Exemptions. \n\n(2) Notwithstanding paragraph (1), a process that has not been included on \n\nthe register specified in Regulation 30, may be carried out if— \n\n(a) \n\n(b) \n\n the related clinical trial had commenced prior to 31 January 2022 \nand is being conducted under Directive 2001/20/EC, or \nthe process relates to a clinical trial conducted under the Clinical \nTrials Regulation whereby an application to be added to the \nRegister of Exemptions has been submitted to the Authority \npursuant to Regulation 32 by 31st of January 2023.", "text_norm": "31 (1) subject paragraph (2) process specified article 61(5) clinical trial regulation shall carried unless included register exemption (2) notwithstanding paragraph (1) process included register specified regulation 30 may carried if-- (a) (b) related clinical trial commenced prior 31 january 2022 conducted directive 2001 20 ec process relates clinical trial conducted clinical trial regulation whereby application added register exemption submitted authority pursuant regulation 32 31st january 2023", "start_char": 35585, "end_char": 36303, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-32", "parent_doc_id": "si-2022-0099", "section_id": "reg-32", "section_label": "Regulation 32.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "32. (1) An application for entry on to the register shall be—", "text_raw": "32. (1) An application for entry on to the register shall be— \n\n(a) made in writing, in accordance with any form and manner as the \n\nAuthority at its discretion may require, \n\n(b) \n\n(c) \n\n(d) \n\nsigned by or on behalf of the applicant, whether in ink or by \nmeans of electronic signature, \n\naccompanied by any fee which may be payable in connection with \nthe application, \n\nsubject to Regulation 31, be submitted prior to the intended \ncommencement of the activity. \n\n(2) The applicant shall notify the Authority without delay of any changes to \n\nthe details of the registered process.", "text_norm": "32 (1) application entry register shall be-- (a) made writing accordance form manner authority discretion may require (b) (c) (d) signed behalf applicant whether ink mean electronic signature accompanied fee may payable connection application subject regulation 31 submitted prior intended commencement activity (2) applicant shall notify authority without delay change detail registered process", "start_char": 36303, "end_char": 36890, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-33", "parent_doc_id": "si-2022-0099", "section_id": "reg-33", "section_label": "Regulation 33.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "33. Following the receipt of an application for entry on the Register of", "text_raw": "33. Following the receipt of an application for entry on the Register of \nExemptions, the Authority may carry out an inspection of the process, as \ndetermined by risk assessment.", "text_norm": "33 following receipt application entry register exemption authority may carry inspection process determined risk assessment", "start_char": 36890, "end_char": 37071, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-34", "parent_doc_id": "si-2022-0099", "section_id": "reg-34", "section_label": "Regulation 34.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "34. The Authority may not include a process on the Register of Exemptions", "text_raw": "34. The Authority may not include a process on the Register of Exemptions \n\nwhere— \n\n \n \n \n \n \n \n\f18 [99] \n\n(a) \n(b) \n\nconditions for entry on to the register are not satisfied, \nthe information submitted is false or misleading.", "text_norm": "34 authority may include process register exemption where-- 18 99 (a) (b) condition entry register satisfied information submitted false misleading", "start_char": 37071, "end_char": 37302, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-35", "parent_doc_id": "si-2022-0099", "section_id": "reg-35", "section_label": "Regulation 35.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "35. The Authority may withdraw a registered process from the Register of", "text_raw": "35. The Authority may withdraw a registered process from the Register of \n\nExemptions where— \n\n(a) \n\nit does not comply with these Regulations or a condition of entry \non to the Register of Exemptions, \n\n(b) \n\nthe applicant requests the withdrawal of the process, \n\n(c) \n\nit transpires that the information submitted in the application for \nentry to the Register of Exemptions is false or misleading. \n\nApplication for manufacturer’s authorisation", "text_norm": "35 authority may withdraw registered process register exemption where-- (a) comply regulation condition entry register exemption (b) applicant request withdrawal process (c) transpires information submitted application entry register exemption false misleading application manufacturer authorisation", "start_char": 37302, "end_char": 37752, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-36", "parent_doc_id": "si-2022-0099", "section_id": "reg-36", "section_label": "Regulation 36.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "36. (1) An application for the grant of a manufacturer’s authorisation under", "text_raw": "36. (1) An application for the grant of a manufacturer’s authorisation under \n\nArticle 61 of the Clinical Trials Regulation shall be— \n\n(a) made in writing to the Authority, \n\n(b) \n\nsigned by or on behalf of the applicant, whether in ink or by \nmeans of an electronic signature, and \n\n(c) \n\naccompanied by— \n\n(i) \n\na written undertaking that in the event of the authorisation \nbeing granted, the applicant will ensure fulfilment of the \nobligations arising by virtue of the terms and conditions of \nthe authorisation, and \n\n(ii) \n\nany fee which may be payable in connection with that \napplication.", "text_norm": "36 (1) application grant manufacturer authorisation article 61 clinical trial regulation shall be-- (a) made writing authority (b) signed behalf applicant whether ink mean electronic signature (c) accompanied by-- (i) written undertaking event authorisation granted applicant ensure fulfilment obligation arising virtue term condition authorisation (ii) fee may payable connection application", "start_char": 37752, "end_char": 38352, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-37", "parent_doc_id": "si-2022-0099", "section_id": "reg-37", "section_label": "Regulation 37.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "37. (1) Subject to the provisions of this Regulation, the Authority shall", "text_raw": "37. (1) Subject to the provisions of this Regulation, the Authority shall \nconsider a valid application for a manufacturer’s authorisation and grant or \nrefuse to grant same within a period not exceeding 90 days from the date the \napplication is received. \n\n(2) Following receipt of an application, the Authority shall, by means of \ninspection or otherwise, confirm the accuracy of the particulars provided in the \napplication and may give a notice in writing to the applicant requesting him or \nher to provide further information relating to the said particulars. \n\n(3) Where the Authority gives a notice pursuant to paragraph (2), the period \nspecified in paragraph (1) shall be suspended from the date the notice is given \nand shall recommence only on receipt of the information requested. \n\n(4) The expiry of the period of 90 days referred to in paragraph (1) shall not \n\nconfer any rights on the applicant, and in particular shall not — \n\n(a) \n\nconfer a default or tacit manufacturer’s authorisation on an \napplicant, or \n\n(b) be taken to imply that a manufacturer’s authorisation has been \n\ngranted or will be granted. \n\n \n \n \n \n \n \n \n\f[99] 19 \n\nGrant or refusal of manufacturer’s authorisation", "text_norm": "37 (1) subject provision regulation authority shall consider valid application manufacturer authorisation grant refuse grant within period exceeding 90 day date application received (2) following receipt application authority shall mean inspection otherwise confirm accuracy particular provided application may give notice writing applicant requesting provide information relating said particular (3) authority give notice pursuant paragraph (2) period specified paragraph (1) shall suspended date notice given shall recommence receipt information requested (4) expiry period 90 day referred paragraph (1) shall confer right applicant particular shall -- (a) confer default tacit manufacturer authorisation applicant (b) taken imply manufacturer authorisation granted granted 99 19 grant refusal manufacturer authorisation", "start_char": 38352, "end_char": 39555, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-38", "parent_doc_id": "si-2022-0099", "section_id": "reg-38", "section_label": "Regulation 38.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "38. (1) The Authority shall not grant a manufacturer’s authorisation unless", "text_raw": "38. (1) The Authority shall not grant a manufacturer’s authorisation unless \n\nit is satisfied that— \n(a) \n(b) \n\nthe particulars supplied pursuant to Regulation 36 are accurate, \nthe applicant has— \n\n(i) \n\ncomplied with the requirements of Regulation 36, and of \nArticle 61 of the Clinical Trials Regulation, and \n\n(ii) provided any additional information to the Authority as \n\nmay have been required under Regulation 37. \n\n(2) Subject to paragraph (1), the Authority may— \n\n(a) grant a manufacturer’s authorisation in respect of any or all of— \n\n(i) \n\n(ii) \n(iii) \n\nthe types and pharmaceutical forms of the investigational \nmedicinal product manufactured or imported, \n\nthe premises, and \nthe manufacturing or importation operations specified in \nthe application , \n\n(b) grant a manufacturer’s authorisation in accordance with the \napplication, but subject to the carrying out of certain obligations \nby the authorisation holder, \n\n(c) \n\ngrant a manufacturer’s authorisation otherwise than in accordance \nwith the application, or \n\n(d) \n\nrefuse to grant a manufacturer’s authorisation. \n\n(3) The provisions of Schedule III shall have effect where the Authority \n\nproposes to— \n\n(a) \n\n grant a manufacturer’s authorisation in accordance with the \napplication, but subject to the carrying out of certain obligations \nby the authorisation holder, \n\n(b) grant a manufacturer’s authorisation otherwise that in accordance \n\nwith the application, or \n\n(c) \n\nrefuse to grant a manufacturer’s authorisation. \n\n(4) Where the Authority grants or refuses to grant an Authorisation in \naccordance with paragraph (2), it shall give the applicant a notice in writing \nstating in detail the reasons on which its decision is based. \n\n(5) The Authority shall enter information in the EudraGMDP database in \n\nrelation to all manufacturer’s authorisations granted. \n\nEffect of manufacturer’s authorisation", "text_norm": "38 (1) authority shall grant manufacturer authorisation unless satisfied that-- (a) (b) particular supplied pursuant regulation 36 accurate applicant has-- (i) complied requirement regulation 36 article 61 clinical trial regulation (ii) provided additional information authority may required regulation 37 (2) subject paragraph (1) authority may-- (a) grant manufacturer authorisation respect of-- (i) (ii) (iii) type pharmaceutical form investigational medicinal product manufactured imported premise manufacturing importation operation specified application (b) grant manufacturer authorisation accordance application subject carrying certain obligation authorisation holder (c) grant manufacturer authorisation otherwise accordance application (d) refuse grant manufacturer authorisation (3) provision schedule iii shall effect authority proposes to-- (a) grant manufacturer authorisation accordance application subject carrying certain obligation authorisation holder (b) grant manufacturer authorisation otherwise accordance application (c) refuse grant manufacturer authorisation (4) authority grant refuse grant authorisation accordance paragraph (2) shall give applicant notice writing stating detail reason decision based (5) authority shall enter information eudragmdp database relation manufacturer authorisation granted effect manufacturer authorisation", "start_char": 39555, "end_char": 41444, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-39", "parent_doc_id": "si-2022-0099", "section_id": "reg-39", "section_label": "Regulation 39.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "39. (1) A manufacturer’s authorisation shall apply and have effect only in", "text_raw": "39. (1) A manufacturer’s authorisation shall apply and have effect only in \n\nrelation to— \n\n(a) \n\nthe types and pharmaceutical forms of investigational medicinal \nproducts manufactured or imported, \n\n \n \n\f20 [99] \n\n(b) \n\nthe manufacturing or importation operations, and \n\n(c) \n\nthe premises, \n\nspecified in the application made pursuant to Regulation 36 and in respect of \nwhich the authorisation has been granted. \n\nObligations of manufacturers of investigational medicinal products", "text_norm": "39 (1) manufacturer authorisation shall apply effect relation to-- (a) type pharmaceutical form investigational medicinal product manufactured imported 20 99 (b) manufacturing importation operation (c) premise specified application made pursuant regulation 36 respect authorisation granted obligation manufacturer investigational medicinal product", "start_char": 41444, "end_char": 41930, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-40", "parent_doc_id": "si-2022-0099", "section_id": "reg-40", "section_label": "Regulation 40.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "40. (1) Subject to Article 63 of the Clinical Trials Regulation and the", "text_raw": "40. (1) Subject to Article 63 of the Clinical Trials Regulation and the \n\nprovisions of these Regulations, an authorisation holder shall not— \n\n(a) manufacture for supply in the EEA, or for export, any \ninvestigational medicinal product except in accordance with the \nrequirements set down in Schedule III and with the principles and \nguidelines of good manufacturing practice set down \nin \n2017/1569 \nCommission Delegated Regulation \nsupplementing the Clinical Trials Regulation, or \n\n(EU) \n\n(b) \n\ninvestigational medicinal products except \n\nimport any \nin \naccordance with the requirements set down in Schedule IV, and \nwith the principles and guidelines of good manufacturing practice \nset down in Commission Delegated Regulation (EU) 2017/1569 \nsupplementing the Clinical Trials Regulation. \n\n(2) An authorisation holder shall comply with the obligations set down in \nSchedule IV, as appropriate, and any further conditions or obligations as may be \nimposed in the authorisation. \n\nVariation of manufacturer’s authorisation", "text_norm": "40 (1) subject article 63 clinical trial regulation provision regulation authorisation holder shall not-- (a) manufacture supply eea export investigational medicinal product except accordance requirement set schedule iii principle guideline good manufacturing practice set 2017 1569 commission delegated regulation supplementing clinical trial regulation (eu) (b) investigational medicinal product except import accordance requirement set schedule iv principle guideline good manufacturing practice set commission delegated regulation (eu) 2017 1569 supplementing clinical trial regulation (2) authorisation holder shall comply obligation set schedule iv appropriate condition obligation may imposed authorisation variation manufacturer authorisation", "start_char": 41930, "end_char": 42960, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-41", "parent_doc_id": "si-2022-0099", "section_id": "reg-41", "section_label": "Regulation 41.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "41. (1) The Authority may vary a manufacturer’s authorisation, whether on", "text_raw": "41. (1) The Authority may vary a manufacturer’s authorisation, whether on \n\nthe application of the authorisation holder or otherwise. \n\n(2) Subject to the provisions of this Regulation, if the authorisation holder \nmakes a valid application to vary any details in respect of the manufacturer’s \nauthorisation which has been granted, the Authority shall consider the \napplication and may vary or refuse to vary the authorisation— \n\n(a) within a period not exceeding 30 days from the date the \napplication is received if an inspection of the premises is not \nrequired, or \n\n(b) within a period not exceeding 90 days from the date the \napplication is received if the Authority deems it necessary to \nconduct an inspection of any premises to which the variation \nrelates. \n\n(3) Following receipt of a valid application to vary a manufacturer’s \nauthorisation, the Authority may give a notice in writing to the applicant \nrequesting him or her to provide further information relating to the contents of \nthe application or any particulars relevant to the application. \n\n(4) Where the Authority gives a notice pursuant to paragraph (3), and a \nperiod specified in paragraph (2) applies, that period shall be suspended from the \n\n \n \n \n\f[99] 21 \n\ndate the notice is given and shall recommence only on receipt of the information \nrequested. \n\n(5) The Authority may vary a manufacturer’s authorisation where it \nconsiders it necessary to do so for the purpose of securing compliance with the \nClinical Trials Regulation, and may make a manufacturer’s authorisation \nconditional on the carrying out of certain obligations.", "text_norm": "41 (1) authority may vary manufacturer authorisation whether application authorisation holder otherwise (2) subject provision regulation authorisation holder make valid application vary detail respect manufacturer authorisation granted authority shall consider application may vary refuse vary authorisation-- (a) within period exceeding 30 day date application received inspection premise required (b) within period exceeding 90 day date application received authority deems necessary conduct inspection premise variation relates (3) following receipt valid application vary manufacturer authorisation authority may give notice writing applicant requesting provide information relating content application particular relevant application (4) authority give notice pursuant paragraph (3) period specified paragraph (2) applies period shall suspended 99 21 date notice given shall recommence receipt information requested (5) authority may vary manufacturer authorisation considers necessary purpose securing compliance clinical trial regulation may make manufacturer authorisation conditional carrying certain obligation", "start_char": 42960, "end_char": 44575, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-42", "parent_doc_id": "si-2022-0099", "section_id": "reg-42", "section_label": "Regulation 42.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "42. (1) The provisions of Schedule III shall have effect where the", "text_raw": "42. (1) The provisions of Schedule III shall have effect where the \n\nAuthority— \n\n(a) proposes to vary a manufacturer’s authorisation, otherwise than \nin accordance with a valid application by the authorisation holder, \n\n(b) proposes to make a manufacturer’s authorisation conditional on \nthe carrying out of certain obligations by the authorisation holder, \nor \n\n(c) \n\nproposes to refuse to vary a manufacturer’s authorisation, after \nconsideration of the application of the holder. \n\n(2) Where the Authority— \n\n(a) varies a manufacturer’s authorisation, otherwise \n\nin \naccordance with the valid application by the authorisation holder, \nor \n\nthan \n\n(b) makes a manufacturer’s authorisation conditional on the carrying \n\nout of certain obligations by the authorisation holder, or \n\n(c) \n\nafter consideration of the application of the holder, refuses to vary \na manufacturer’s authorisation, \n\nthe Authority shall notify the holder of that authorisation in writing, stating in \ndetail the reasons on which its decision is based. \n\n(3) In this Regulation, “valid application” means an application— \n\n(a) made to the Authority in writing and signed by or on behalf of the \napplicant, whether in ink or by means of an electronic signature, \n\n(b) \n\nspecifying the variation requested by the applicant, \n\n(c) \n\naccompanied by— \n\n(i) \n\nsuch particulars and supporting documentation as are \nnecessary \nthe \napplication, and \n\nthe Authority \n\nto consider \n\nto enable \n\n(ii) \n\nany fee which may be payable in connection with that \napplication. \n\nSuspension and revocation of manufacturer’s authorisation", "text_norm": "42 (1) provision schedule iii shall effect authority-- (a) proposes vary manufacturer authorisation otherwise accordance valid application authorisation holder (b) proposes make manufacturer authorisation conditional carrying certain obligation authorisation holder (c) proposes refuse vary manufacturer authorisation consideration application holder (2) authority-- (a) varies manufacturer authorisation otherwise accordance valid application authorisation holder (b) make manufacturer authorisation conditional carrying certain obligation authorisation holder (c) consideration application holder refuse vary manufacturer authorisation authority shall notify holder authorisation writing stating detail reason decision based (3) regulation valid application mean application-- (a) made authority writing signed behalf applicant whether ink mean electronic signature (b) specifying variation requested applicant (c) accompanied by-- (i) particular supporting documentation necessary application authority consider enable (ii) fee may payable connection application suspension revocation manufacturer authorisation", "start_char": 44575, "end_char": 46173, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-43", "parent_doc_id": "si-2022-0099", "section_id": "reg-43", "section_label": "Regulation 43.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "43. (1) The Authority may by a notice in writing to the authorisation holder,", "text_raw": "43. (1) The Authority may by a notice in writing to the authorisation holder, \nforthwith or from a date specified in the notice, suspend the authorisation for \n\n \n \n \n\f22 [99] \n\nsuch period as the Authority may determine, or revoke the authorisation, on one \nor more of the following grounds— \n\n(a) \n\n(b) \n\n(c) \n\n(d) \n\n(e) \n\n(f) \n\n(g) \n\nthe holder is not carrying out or has indicated by a notice in \nwriting that he or she is no longer to carry out, the manufacturing \nor importation operations to which the authorisation relates, \n\nthe matters specified in the application in accordance with \nRegulation 36 were false or incomplete in a material particular, \n\na material change of circumstances has occurred in relation to any \nof those matters or particulars, \n\nthe authorisation holder has failed to any material extent to \ncomply with his or her obligations under Regulation 40, \n\nthe holder has manufactured or \ninvestigational \nmedicinal products otherwise than in accordance with the terms \nof the authorisation, \n\nimported \n\nthe authorisation holder does not have the staff, premises, \nequipment or facilities necessary for carrying out properly the \nhandling, storage, or distribution activities to which the \nauthorisation relates, and \n\nthe authorisation holder has failed to carry out an obligation \nimposed by the Authority pursuant to Regulation 38(2)(b) or \nRegulation 42(2)(b). \n\n(2) The suspension or revocation of a manufacturer’s authorisation under \n\nthis Regulation may be— \n\n(a) \n\n(b) \n\ntotal, or \n\nlimited to— \n\n(i) \n\ncertain manufacturing or importation operations concerning \nmedicinal products, or \n\n(ii) \n\nparticular premises or particular parts of any premises \n\ndescribed in the manufacturer’s authorisation. \n\n(3) The provisions of Schedule III shall have effect where the Authority \nproposes to suspend or revoke a manufacturer’s authorisation in accordance with \nthis Regulation. \n\n(4) Where the Authority suspends or revokes a manufacturer’s authorisation \nin accordance with this Regulation, it shall notify the authorisation holder in \nwriting, stating in detail the reasons on which its decision to suspend or revoke \nthe authorisation is based. \n\n \n \n \n\f[99] 23 \n\nPART 9 \n\nFEES", "text_norm": "43 (1) authority may notice writing authorisation holder forthwith date specified notice suspend authorisation 22 99 period authority may determine revoke authorisation one following grounds-- (a) (b) (c) (d) (e) (f) (g) holder carrying indicated notice writing longer carry manufacturing importation operation authorisation relates matter specified application accordance regulation 36 false incomplete material particular material change circumstance occurred relation matter particular authorisation holder failed material extent comply obligation regulation 40 holder manufactured investigational medicinal product otherwise accordance term authorisation imported authorisation holder staff premise equipment facility necessary carrying properly handling storage distribution activity authorisation relates authorisation holder failed carry obligation imposed authority pursuant regulation 38(2)(b) regulation 42(2)(b) (2) suspension revocation manufacturer authorisation regulation may be-- (a) (b) total limited to-- (i) certain manufacturing importation operation concerning medicinal product (ii) particular premise particular part premise described manufacturer authorisation (3) provision schedule iii shall effect authority proposes suspend revoke manufacturer authorisation accordance regulation (4) authority suspends revoke manufacturer authorisation accordance regulation shall notify authorisation holder writing stating detail reason decision suspend revoke authorisation based 99 23 part 9 fee", "start_char": 46173, "end_char": 48391, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-44", "parent_doc_id": "si-2022-0099", "section_id": "reg-44", "section_label": "Regulation 44.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "44. (1) In accordance with Article 86 of the Clinical Trials Regulation, the", "text_raw": "44. (1) In accordance with Article 86 of the Clinical Trials Regulation, the \n\nAuthority may, \n\n(a) without prejudice to subparagraph (b), charge a fee, or fees, to the \n\nsponsor for: \n\n(i) \n\n(ii) \n\nthe assessment of clinical trial applications under Chapter \nII of the Clinical Trials Regulation and Regulations 8 and 9 \nof these Regulations, and \n\nthe assessment of applications for substantial modifications \nunder Chapter III of the Clinical Trials Regulation and \nRegulation 12 of these Regulations; \n\n(iii) consideration of an appeal submitted in accordance with \nPart 10 of these Regulations and Part 5 of S.I. No. 41 of \n2022; \n\n(iv) \n\nthe review of safety reports submitted by sponsors; \n\n(v) \n\nthe inspection of a clinical trial site, or of a sponsor site, or \nof a site of any other entity involved in the conduct of a \nclinical trial. \n\n(b) \n\ncharge a reduced fee, or fees, to non-commercial sponsors, for the \nactivities under paragraph (1)(a)(i) or (ii)). \n\n(2) The amount of the fee, or fees, under paragraph (1)(a) and (b) shall be— \n\n(a) \n\nreviewed on an annual basis by the Authority and the National \nOffice and approved by the Minister, and \n\n(b) published on the websites of the Authority and the National \n\nOffice. \n\n(3) The fees under paragraph (1)(a) and (b) shall be— \n\n(a) payable immediately upon submission of a clinical trial \napplication through the EU portal in accordance with Article 5 \nand Article 14 of the Clinical Trials Regulation; \n\n(b) where applicable, payable immediately upon submission of a \nsubstantial modification application through the EU portal in \naccordance with Article 16 of the Clinical Trials Regulation; \n\n(c) \n\nnon-refundable once the application for a clinical trial application \nor substantial modification application has been validated in \naccordance with Article 5, Article 17 or Article 20 of the Clinical \nTrials Regulation, as appropriate. \n\n(4) The Authority shall remit a regular payment to the National Office in \nrespect of the ethical review of applications for clinical trials and \nsubstantial modifications. \n\n \n \n\f24 [99] \n\n(5) The Authority may charge fees in relation to an application for the grant \nor variation of a manufacturer’s authorisation and inspection of a \nmanufacturing site. \n\n(6) The Authority may charge fees in relation to applications to the Register \nof Exemptions, and in relation to the inspection of manufacturers and \nprocesses under that Register. \n\nPART 10 \n\nAPPEALS", "text_norm": "44 (1) accordance article 86 clinical trial regulation authority may (a) without prejudice subparagraph (b) charge fee fee sponsor (i) (ii) assessment clinical trial application chapter ii clinical trial regulation regulation 8 9 regulation assessment application substantial modification chapter iii clinical trial regulation regulation 12 regulation (iii) consideration appeal submitted accordance part 10 regulation part 5 s.i no 41 2022 (iv) review safety report submitted sponsor (v) inspection clinical trial site sponsor site site entity involved conduct clinical trial (b) charge reduced fee fee non-commercial sponsor activity paragraph (1)(a)(i) (ii)) (2) amount fee fee paragraph (1)(a) (b) shall be-- (a) reviewed annual basis authority national office approved minister (b) published website authority national office (3) fee paragraph (1)(a) (b) shall be-- (a) payable immediately upon submission clinical trial application eu portal accordance article 5 article 14 clinical trial regulation (b) applicable payable immediately upon submission substantial modification application eu portal accordance article 16 clinical trial regulation (c) non-refundable application clinical trial application substantial modification application validated accordance article 5 article 17 article 20 clinical trial regulation appropriate (4) authority shall remit regular payment national office respect ethical review application clinical trial substantial modification 24 99 (5) authority may charge fee relation application grant variation manufacturer authorisation inspection manufacturing site (6) authority may charge fee relation application register exemption relation inspection manufacturer process register part 10 appeal", "start_char": 48391, "end_char": 50861, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-45", "parent_doc_id": "si-2022-0099", "section_id": "reg-45", "section_label": "Regulation 45.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "45. (1) A sponsor may, within the time limit specified under paragraph (2),", "text_raw": "45. (1) A sponsor may, within the time limit specified under paragraph (2), \ngive notice to the Authority of his or her wish to submit an appeal in respect of \na refusal to— \n\n(a) \n\n(b) \n\n(c) \n\nauthorise a clinical trial pursuant to Article 8(4) of the Clinical \nTrials Regulation, and under these Regulations, \n\nauthorise a clinical trial pursuant to Article 14(10) of the Clinical \nTrials Regulation, and under these Regulations, or \n\nauthorise a substantial modification pursuant to Articles 19(2), \n20(7) or 23(4) of the Clinical Trials Regulation, and under these \nRegulations. \n\n(2) Any appeal shall be submitted to the Authority within 28 days of receipt \n\nof a refusal specified in paragraph (1). \n\n(3) The provisions of Schedule I, and of Part 5 of S.I. No. 41 of 2022, shall \napply to the submission and processing of an appeal submitted by a sponsor \nunder paragraph (1). \n\nPART 11 \n\nLANGUAGE \n\nApplication dossier", "text_norm": "45 (1) sponsor may within time limit specified paragraph (2) give notice authority wish submit appeal respect refusal to-- (a) (b) (c) authorise clinical trial pursuant article 8(4) clinical trial regulation regulation authorise clinical trial pursuant article 14(10) clinical trial regulation regulation authorise substantial modification pursuant article 19(2) 20(7) 23(4) clinical trial regulation regulation (2) appeal shall submitted authority within 28 day receipt refusal specified paragraph (1) (3) provision schedule part 5 s.i no 41 2022 shall apply submission processing appeal submitted sponsor paragraph (1) part 11 language application dossier", "start_char": 50861, "end_char": 51789, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-46", "parent_doc_id": "si-2022-0099", "section_id": "reg-46", "section_label": "Regulation 46.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "46. For clinical trials to be conducted in the State and for the purposes of", "text_raw": "46. For clinical trials to be conducted in the State and for the purposes of \n\nArticle 26 of the Clinical Trials Regulation, the \n\n(1) application dossier described under Article 25 of the Clinical Trials \n\nRegulation, and \n\n(2) any documentation addressed to subjects, \n\nshall be in English. \n\nLabelling", "text_norm": "46 clinical trial conducted state purpose article 26 clinical trial regulation (1) application dossier described article 25 clinical trial regulation (2) documentation addressed subject shall english labelling", "start_char": 51789, "end_char": 52096, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-47", "parent_doc_id": "si-2022-0099", "section_id": "reg-47", "section_label": "Regulation 47.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "47. (1) For the purposes of Article 69 of the Clinical Trials Regulation and", "text_raw": "47. (1) For the purposes of Article 69 of the Clinical Trials Regulation and \nwithout prejudice to paragraph (2), the language of the information required to \n\n \n \n \n \n \n \n\f[99] 25 \n\nappear on the label of an authorised or unauthorised investigational medicinal \nproduct or auxiliary medicinal product used in a clinical trial shall be English. \n\n(2) Paragraph (1) shall not preclude the information specified therein also \n\nappearing on the label in one or more languages, other than English. \n\nPART 12 \n\nOFFENCES, PENALTIES, AND ENFORCEMENT \n\nOffences", "text_norm": "47 (1) purpose article 69 clinical trial regulation without prejudice paragraph (2) language information required 99 25 appear label authorised unauthorised investigational medicinal product auxiliary medicinal product used clinical trial shall english (2) paragraph (1) shall preclude information specified therein also appearing label one language english part 12 offence penalty enforcement offence", "start_char": 52096, "end_char": 52652, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-48", "parent_doc_id": "si-2022-0099", "section_id": "reg-48", "section_label": "Regulation 48.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "48. (1) A person who—", "text_raw": "48. (1) A person who— \n\n(a) \n\n(b) \n\n(c) \n\ncommences a clinical trial in the State without— \n(i) \n\nnotification of authorisation, in accordance with Regulation \n10, or \n\n(ii) having in place a scheme to provide compensation for any \ndamage suffered by a subject resulting from a clinical trial \nin accordance with Regulation 17, \n\ncommences a substantial modification to a clinical trial without \nnotification of authorisation in accordance with Regulation 13, \n\nconducts a clinical trial, other than in accordance with the \nrequirements of Regulation 14, \n\n(d) performs the functions of the sponsor of a clinical trial (whether \nthat person is the sponsor or is acting under arrangements made \nwith that sponsor), other than in accordance with the requirements \nof Regulation 14, \n\n(e) \n\n(f) \n\n(g) \n\n(h) \n\n(i) \n\n(j) \n\nperforms the functions of the investigator of a clinical trial, other \nthan in accordance with the requirements of Regulation 14, \n\ncharges a fee to a subject of a clinical trial other than in \naccordance with Regulation 16, \n\nfails to maintain a trial master file in accordance with the \nrequirements of Article 57 of the Clinical Trials Regulation and \nRegulation 20, \n\nfails to make available to the Authority a trial master file in \naccordance with the time periods set out in Regulation 20(2), \n\nfails to meet their obligations in relation to archiving under \nArticle 58 of the Clinical Trials Regulation and Regulation 21(1), \n\nfails to retain the medical files of clinical trial subjects in \naccordance with Regulation 21(2), \n\n(k) \n\nfails to pay a fee due under Regulation 44, \n\n(l) \n\n(m) \n\nlabels, sells, or supplies a medicinal product or auxiliary \nmedicinal product other than in accordance with Regulation 47, \n\nfails to comply with a notice of suspension or termination served \nunder Regulation 24 or 43, unless same has been withdrawn or \nrevoked by the Authority, \n\n \n \n \n\f26 [99] \n\n(n) \n\nin— \n(i) \n\n(ii) \n\nan application for an ethics committee opinion, \n\nan application for authorisation under Chapter II of the \nClinical Trials Regulation to conduct a clinical trial in the \nState, \n\n(iii) an application for a substantial modification to a previously \nauthorised clinical trial under Chapter III of the Clinical \nTrials Regulation, \n\nprovides to the Authority, the nominated ethics committee, or the \nNational Office any relevant information which is false or \nmisleading in a material particular, \n\n(o) \n\nin— \n\n(i) \n\nthe conduct of a clinical trial authorised in accordance with \nthese Regulations, \n\n(ii) \n\nthe sponsorship of such a clinical trial, \n\n(iii) \n\nthe performance of the functions of a sponsor, when acting \nunder arrangements made with the sponsor of such a \nclinical trial, \n\n(iv) the performance of the duties of a qualified person in \nthe Clinical Trials \n\naccordance with Article 61 of \nRegulation, \n\n(v) \n\nthe holding of a manufacturing authorisation, \n\n(vi) securing or maintaining a listing on the Register of \n\nExemptions \n\nprovides to the Authority, the nominated ethics committee or the \nNational Office any relevant information which is false or \nmisleading in a material particular, \n\n(p) wilfully obstructs or interferes with the exercise of a power by an \n\nauthorised officer pursuant to Regulation 54, \n\n(q) without reasonable excuse, fails to comply with any request made \n\nby an authorised officer under Regulation 54, \n\n(r) \n\n(s) \n\n(t) \n\n(u) \n\n(v) \n\nfails to comply with the provisions laid down in the Clinical Trials \nRegulations on the submission of information intended to be \nmade publicly available to the EU database, \n\nfails to comply with safety reporting requirements as laid down \nin Articles 41, 42 and 43 of the Clinical Trials Regulation, \n\nfails to provide records requested by the Authority in accordance \nwith Regulation 25(2), \n\nfails to meet the requirements of Article 54 of the Clinical Trials \nRegulation in relation to Urgent Safety measures, \n\nfails to establish a legal representative in accordance with Article \n74(1) of the Clinical Trials Regulation when required, \n\n \n\f[99] 27 \n\n(w) \n\nfails to meet the requirements of the Clinical Trials Regulation, \nor of Part 4 of these Regulations, in relation to the protection of \nclinical trial subjects and informed consent, \n\n(x) \n\n(y) \n\n(z) \n\nfails to comply with the requirements for the manufacture and \nimport of investigational medicinal products and auxiliary \nmedicinal products in accordance with Regulation 40, \n\nsells or supplies an investigational medicinal product for the \npurposes of a clinical trial knowing or having reasonable cause to \nsuspect that it was manufactured, labelled, packaged or imported \nin contravention of Regulation 40, \n\notherwise than for the purpose of performing or exercising a duty \nor power imposed or conferred by or under these Regulations, is \nin possession of an investigational medicinal product knowing or \nhaving reasonable cause to suspect that it was imported in \ncontravention of Regulation 40, \n\n(aa) fails to comply with the requirements for notifications and \nsubmissions laid down in Article 36, 37, and 38 of the Clinical \nTrials Regulation, \n\nis guilty of an offence. \n\n(2) The offences listed in paragraph (1) also apply to a legal representative \nof a sponsor responsible for ensuring compliance with the sponsor’s obligations \nin the State pursuant to Article 74(1) of the Clinical Trials Regulation. \n\nPenalties", "text_norm": "48 (1) person who-- (a) (b) (c) commences clinical trial state without-- (i) notification authorisation accordance regulation 10 (ii) place scheme provide compensation damage suffered subject resulting clinical trial accordance regulation 17 commences substantial modification clinical trial without notification authorisation accordance regulation 13 conduct clinical trial accordance requirement regulation 14 (d) performs function sponsor clinical trial (whether person sponsor acting arrangement made sponsor) accordance requirement regulation 14 (e) (f) (g) (h) (i) (j) performs function investigator clinical trial accordance requirement regulation 14 charge fee subject clinical trial accordance regulation 16 fails maintain trial master file accordance requirement article 57 clinical trial regulation regulation 20 fails make available authority trial master file accordance time period set regulation 20(2) fails meet obligation relation archiving article 58 clinical trial regulation regulation 21(1) fails retain medical file clinical trial subject accordance regulation 21(2) (k) fails pay fee due regulation 44 (l) (m) label sell supply medicinal product auxiliary medicinal product accordance regulation 47 fails comply notice suspension termination served regulation 24 43 unless withdrawn revoked authority 26 99 (n) in-- (i) (ii) application ethic committee opinion application authorisation chapter ii clinical trial regulation conduct clinical trial state (iii) application substantial modification previously authorised clinical trial chapter iii clinical trial regulation provides authority nominated ethic committee national office relevant information false misleading material particular (o) in-- (i) conduct clinical trial authorised accordance regulation (ii) sponsorship clinical trial (iii) performance function sponsor acting arrangement made sponsor clinical trial (iv) performance duty qualified person clinical trial accordance article 61 regulation (v) holding manufacturing authorisation (vi) securing maintaining listing register exemption provides authority nominated ethic committee national office relevant information false misleading material particular (p) wilfully obstructs interferes exercise power authorised officer pursuant regulation 54 (q) without reasonable excuse fails comply request made authorised officer regulation 54 (r) (s) (t) (u) (v) fails comply provision laid clinical trial regulation submission information intended made publicly available eu database fails comply safety reporting requirement laid article 41 42 43 clinical trial regulation fails provide record requested authority accordance regulation 25(2) fails meet requirement article 54 clinical trial regulation relation urgent safety measure fails establish legal representative accordance article 74(1) clinical trial regulation required 99 27 (w) fails meet requirement clinical trial regulation part 4 regulation relation protection clinical trial subject informed consent (x) (y) (z) fails comply requirement manufacture import investigational medicinal product auxiliary medicinal product accordance regulation 40 sell supply investigational medicinal product purpose clinical trial knowing reasonable cause suspect manufactured labelled packaged imported contravention regulation 40 otherwise purpose performing exercising duty power imposed conferred regulation possession investigational medicinal product knowing reasonable cause suspect imported contravention regulation 40 (aa) fails comply requirement notification submission laid article 36 37 38 clinical trial regulation guilty offence (2) offence listed paragraph (1) also apply legal representative sponsor responsible ensuring compliance sponsor obligation state pursuant article 74(1) clinical trial regulation penalty", "start_char": 52652, "end_char": 58070, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-49", "parent_doc_id": "si-2022-0099", "section_id": "reg-49", "section_label": "Regulation 49.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "49. (1) A person guilty of an offence under these Regulations shall be liable", "text_raw": "49. (1) A person guilty of an offence under these Regulations shall be liable \non summary conviction to a fine not exceeding €3,000, or to imprisonment for a \nterm not exceeding six months, or both. \n\n(2) A person guilty of an offence under these Regulations shall be liable on \nconviction on indictment to a fine not exceeding €300,000, or to imprisonment \nfor a term not exceeding 3 years, or both. \n\nBody corporate", "text_norm": "49 (1) person guilty offence regulation shall liable summary conviction fine exceeding eur3 000 imprisonment term exceeding six month both (2) person guilty offence regulation shall liable conviction indictment fine exceeding eur300 000 imprisonment term exceeding 3 year both body corporate", "start_char": 58070, "end_char": 58490, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-50", "parent_doc_id": "si-2022-0099", "section_id": "reg-50", "section_label": "Regulation 50.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "50. Where an offence under these Regulations is committed by a body", "text_raw": "50. Where an offence under these Regulations is committed by a body \ncorporate and is proved to have been so committed with the consent, connivance \nor approval of or to have been attributable to the wilful neglect on the part of any \nperson, being a director, manager, qualified person, secretary or other officer of \nthe body corporate or a person who was purporting to act in any such capacity, \nthat person as well as the body corporate shall be guilty of an offence and shall \nbe liable to be proceeded against and punished as if he or she was guilty of the \nfirst mentioned offence. \n\nSeparate contraventions", "text_norm": "50 offence regulation committed body corporate proved committed consent connivance approval attributable wilful neglect part person director manager qualified person secretary officer body corporate person purporting act capacity person well body corporate shall guilty offence shall liable proceeded punished guilty first mentioned offence separate contravention", "start_char": 58490, "end_char": 59107, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-51", "parent_doc_id": "si-2022-0099", "section_id": "reg-51", "section_label": "Regulation 51.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "51. For the purposes of these Regulations, every contravention of a provision", "text_raw": "51. For the purposes of these Regulations, every contravention of a provision \nof these Regulations shall be deemed a separate contravention and every \ncontravention of a paragraph or a subparagraph shall also be deemed to be a \n\n \n \n \n \n \n\f28 [99] \n\nseparate contravention and shall carry the same penalty as for a single \ncontravention of any such provision. \n\nInfringement notices", "text_norm": "51 purpose regulation every contravention provision regulation shall deemed separate contravention every contravention paragraph subparagraph shall also deemed 28 99 separate contravention shall carry penalty single contravention provision infringement notice", "start_char": 59107, "end_char": 59493, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-52", "parent_doc_id": "si-2022-0099", "section_id": "reg-52", "section_label": "Regulation 52.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "52. (1) If the Authority has objective grounds for considering that any", "text_raw": "52. (1) If the Authority has objective grounds for considering that any \nperson has contravened any provision of these Regulations, it may serve upon \nthat person a notice in writing (in these Regulations referred to as an \n“infringement notice”) – \n\n(a) \n\ninforming him or her of the Authority’s grounds for considering \nthat the person has contravened one or more of those provisions, \n\n(b) \n\nspecifying the relevant provision of these Regulations, \n\n(c) \n\nspecifying the measures which the person must take in order to \nensure that the contravention does not continue or, as the case \nmay be, does not recur, \n\n(d) \n\nrequiring the person to take those measures, within such period as \nmay be specified in the notice, \n\n(e) warning the person that unless the requirements of subparagraph \n(d) are met, further action may be taken in respect of the \ncontravention. \n\n(2) An infringement notice may include directions as to the measures to be \ntaken by the person on whom the notice is served to ensure that the contravention \ndoes not continue or, as the case may be, does not recur, including the different \nways of securing compliance. \n\n(3) If the Authority serves an infringement notice in accordance with \n\nparagraph (1), it shall forthwith inform the nominated ethics committee. \n\nDefence of due diligence", "text_norm": "52 (1) authority objective ground considering person contravened provision regulation may serve upon person notice writing (in regulation referred infringement notice ) - (a) informing authority ground considering person contravened one provision (b) specifying relevant provision regulation (c) specifying measure person must take order ensure contravention continue case may recur (d) requiring person take measure within period may specified notice (e) warning person unless requirement subparagraph (d) met action may taken respect contravention (2) infringement notice may include direction measure taken person notice served ensure contravention continue case may recur including different way securing compliance (3) authority serf infringement notice accordance paragraph (1) shall forthwith inform nominated ethic committee defence due diligence", "start_char": 59493, "end_char": 60808, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-53", "parent_doc_id": "si-2022-0099", "section_id": "reg-53", "section_label": "Regulation 53.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "53. In any proceedings for an offence under any of the preceding provisions of", "text_raw": "53. In any proceedings for an offence under any of the preceding provisions of \nthese Regulations, it shall be a good defence for a person charged to show \nthat he or she reasonably believed that the said provisions had been \ncomplied with. \n\nEnforcement generally", "text_norm": "53 proceeding offence preceding provision regulation shall good defence person charged show reasonably believed said provision complied with enforcement generally", "start_char": 60808, "end_char": 61075, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-54", "parent_doc_id": "si-2022-0099", "section_id": "reg-54", "section_label": "Regulation 54.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "54. (1) These Regulations and the provisions of the Clinical Trials", "text_raw": "54. (1) These Regulations and the provisions of the Clinical Trials \n\nRegulation to which they refer, shall be enforced by the Authority. \n\n(2) In carrying out its compliance and enforcement role under the Clinical \nTrials Regulation and these Regulations, the Authority shall ensure that \nconfidentiality is respected by authorised officers and other experts engaged in \ngood clinical practice inspections and, with regard to personal data, that the \nrequirements of the General Data Protection Regulation and the Data Protection \nActs 1988 to 2018 are respected. \n\nAppointment of authorised officers", "text_norm": "54 (1) regulation provision clinical trial regulation refer shall enforced authority (2) carrying compliance enforcement role clinical trial regulation regulation authority shall ensure confidentiality respected authorised officer expert engaged good clinical practice inspection regard personal data requirement general data protection regulation data protection act 1988 2018 respected appointment authorised officer", "start_char": 61075, "end_char": 61679, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-55", "parent_doc_id": "si-2022-0099", "section_id": "reg-55", "section_label": "Regulation 55.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "55. (1) For the purposes of ensuring compliance with the Clinical Trials", "text_raw": "55. (1) For the purposes of ensuring compliance with the Clinical Trials \nRegulation and these Regulations, the Chief Executive of the Authority may \n\n \n \n \n \n \n\f[99] 29 \n\nappoint such and so many persons as he or she thinks fit to be authorised officers, \nand each authorised officer shall be furnished with a warrant of appointment. \n\n(2) An authorised officer shall, when performing a function imposed on an \nauthorised officer under these Regulations, produce his or her warrant for \ninspection if requested to do so by a person affected by the performance of that \nfunction. \n\nFunctions of authorised officers", "text_norm": "55 (1) purpose ensuring compliance clinical trial regulation regulation chief executive authority may 99 29 appoint many person think fit authorised officer authorised officer shall furnished warrant appointment (2) authorised officer shall performing function imposed authorised officer regulation produce warrant inspection requested person affected performance function function authorised officer", "start_char": 61679, "end_char": 62296, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-56", "parent_doc_id": "si-2022-0099", "section_id": "reg-56", "section_label": "Regulation 56.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "56. (1) An authorised officer shall carry out such inspections as are", "text_raw": "56. (1) An authorised officer shall carry out such inspections as are \n\nnecessary to enforce these Regulations and the Clinical Trials Regulation. \n\n(2) Without prejudice to paragraph (1), good clinical practice inspections \n\nmay be carried out on any of the following occasions— \n\n(a) before, during or after the conduct of clinical trials; \n(b) \n\nas part of the verification of applications for a manufacturing or \nmarketing authorisation; \nas a follow-up to the granting of authorisation; \n\n(c) \n(d) where services are provided for the support of clinical trials. \n(3) Subject to paragraphs (4) and (5) an authorised officer may, for the \npurpose of ensuring that these Regulations are being complied with, carry \nout all or any of the following acts— \n\n(a) \n\n(b) \n\n(c) \n\n(d) \n\n(e) \n\n(f) \n\n(g) \n\n(h) \n\n(i) \n\nat all reasonable times, enter (if necessary, by the use of \nreasonable force) and search a premises of any class or \ndescription, \n\ninspect any substance or product which is stored, or offered or \nkept for sale or supply at such premises, \n\nrequire the production of, inspect and, if he or she thinks fit, take \ncopies of any book, invoice, order, record, register, or other \ndocument or of any entry in any such book, invoice, order, record, \nregister, or other document at such premises, \n\ninspect and copy or extract information from any data (including \npersonal data) within the meaning of the General Data Protection \nRegulation and the Data Protection Acts 1988 to 2018, \n\ntake (with or without payment) samples of any investigational \nmedicinal product or substance stored, or offered or kept for sale \nor supply at such premises for test, examination or analysis, \n\ndetain and if necessary seize any investigational medicinal \nproduct, substance or article, \n\ntake any document which he or she has reasonable cause to \nbelieve to be a document which may be required as evidence in \nproceedings under these Regulations, \n\ninspect and take copies, or samples of, labels used, or intended to \nbe used on an investigational medicinal product, \n\nrequire any person carrying on, or who has carried on, an activity \nto which these Regulations relate, or any person currently or \npreviously employed in connection with such an activity, to give \n\n \n \n\f30 [99] \n\nto the authorised officer such information as the authorised officer \nmay reasonably require for the purposes of these Regulations, \n\n(j) \n\n(k) \n\n(l) \n\ntake photographs of premises and equipment, \n\ncontact the subject of a clinical trial directly, in accordance with \nArticle 10(6) of Regulation (EU) 2017/556, and \n\nask any representative or member of staff of the inspected entity \nand any party involved in the clinical trial for explanations \nrelating to the subject matter and purpose of the inspection and \nrecord the answer. \n\n(4) An authorised officer shall not, other than with the consent of the \noccupier, enter a private dwelling unless he or she has obtained a warrant from \nthe District Court under paragraph (9) authorising such entry. \n\n(5) Any expert who accompanies an authorised officer may: \n\n(a) \n\nask any representative or member of staff of the inspected entity \nand any party involved in the clinical trial for explanations \nrelating to the subject matter and purpose of the inspection and \nrecord the answer, \n\n(b) \n\nreview, record, and extract information from any data (including \npersonal data) within the meaning of the General Data Protection \nRegulation and the Data Protection Acts 1988 to 2018. \n(6) When exercising a power under this Regulation, an authorised officer \nmay, subject to any warrant under paragraph (9), be accompanied by such \nnumber of— \n\n(a) \n\nother authorised officers, \n\ninspectors from the competent authority of another Member State, \n(b) \npersons with expertise relevant to the aspects being examined, or \n(c) \n(d) members of An Garda Síochána or Customs and Excise Officers, \n\nas he or she considers appropriate, in the circumstances of the case. \n\n(7) An authorised officer, for the purpose of exercising any of the powers \nconferred on him or her by paragraph (3), may require any other person, having \nauthority to do so, to break open any container or package or to permit him or \nher to do so. \n\n(8) Where an authorised officer seizes any medicinal product, substance, \narticle or document in the exercise of a power conferred on him or her by \nparagraph (3), he or she shall inform the person from whom it is seized. \n\n(9) If a judge of the District Court is satisfied, on the sworn information of \nan authorised officer, that there are reasonable grounds to authorise entry into \nany premises referred to in paragraph (4), the judge may issue a warrant \nauthorising such an authorised officer, accompanied, if appropriate, by other \nauthorised officers or by a member or members of the Garda Síochána, or both, \nat any time or times within one month from the date of issue of the warrant, on \nproduction of the warrant if requested, to enter those premises or part thereof \nand to exercise any of the powers conferred on such an authorised officer under \nthis Regulation. \n\n(10) A person shall not wilfully obstruct or interfere with the exercise of a \n\npower by an authorised officer pursuant to this Regulation. \n\n \n\f[99] 31 \n\n(11) A person shall not, without reasonable excuse, fail to comply with any \n\nrequest made by an authorised officer under this Regulation. \n\n(12) Any material taken away by an authorised officer under this Regulation \n\nmay be retained by him or her for use in evidence in any proceedings. \n\nProsecution of offences", "text_norm": "56 (1) authorised officer shall carry inspection necessary enforce regulation clinical trial regulation (2) without prejudice paragraph (1) good clinical practice inspection may carried following occasions-- (a) conduct clinical trial (b) part verification application manufacturing marketing authorisation follow-up granting authorisation (c) (d) service provided support clinical trial (3) subject paragraph (4) (5) authorised officer may purpose ensuring regulation complied carry following acts-- (a) (b) (c) (d) (e) (f) (g) (h) (i) reasonable time enter (if necessary use reasonable force) search premise class description inspect substance product stored offered kept sale supply premise require production inspect think fit take copy book invoice order record register document entry book invoice order record register document premise inspect copy extract information data (including personal data) within meaning general data protection regulation data protection act 1988 2018 take (with without payment) sample investigational medicinal product substance stored offered kept sale supply premise test examination analysis detain necessary seize investigational medicinal product substance article take document reasonable cause believe document may required evidence proceeding regulation inspect take copy sample label used intended used investigational medicinal product require person carrying carried activity regulation relate person currently previously employed connection activity give 30 99 authorised officer information authorised officer may reasonably require purpose regulation (j) (k) (l) take photograph premise equipment contact subject clinical trial directly accordance article 10(6) regulation (eu) 2017 556 ask representative member staff inspected entity party involved clinical trial explanation relating subject matter purpose inspection record answer (4) authorised officer shall consent occupier enter private dwelling unless obtained warrant district court paragraph (9) authorising entry (5) expert accompanies authorised officer may (a) ask representative member staff inspected entity party involved clinical trial explanation relating subject matter purpose inspection record answer (b) review record extract information data (including personal data) within meaning general data protection regulation data protection act 1988 2018 (6) exercising power regulation authorised officer may subject warrant paragraph (9) accompanied number of-- (a) authorised officer inspector competent authority another member state (b) person expertise relevant aspect examined (c) (d) member garda siochana custom excise officer considers appropriate circumstance case (7) authorised officer purpose exercising power conferred paragraph (3) may require person authority break open container package permit so (8) authorised officer seizes medicinal product substance article document exercise power conferred paragraph (3) shall inform person seized (9) judge district court satisfied sworn information authorised officer reasonable ground authorise entry premise referred paragraph (4) judge may issue warrant authorising authorised officer accompanied appropriate authorised officer member member garda siochana time time within one month date issue warrant production warrant requested enter premise part thereof exercise power conferred authorised officer regulation (10) person shall wilfully obstruct interfere exercise power authorised officer pursuant regulation 99 31 (11) person shall without reasonable excuse fail comply request made authorised officer regulation (12) material taken away authorised officer regulation may retained use evidence proceeding prosecution offence", "start_char": 62296, "end_char": 67881, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-57", "parent_doc_id": "si-2022-0099", "section_id": "reg-57", "section_label": "Regulation 57.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "57. Proceedings in relation to a summary offence under these Regulations", "text_raw": "57. Proceedings in relation to a summary offence under these Regulations \n\nmay be brought and prosecuted by the Authority. \n\nPART 13 \n\nJOINT CONTROLLERSHIP ARRANGEMENT", "text_norm": "57 proceeding relation summary offence regulation may brought prosecuted authority part 13 joint controllership arrangement", "start_char": 67881, "end_char": 68051, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-58", "parent_doc_id": "si-2022-0099", "section_id": "reg-58", "section_label": "Regulation 58.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "58. The Authority and the National Office shall be the State’s joint", "text_raw": "58. The Authority and the National Office shall be the State’s joint \ncontrollers for the purpose of processing personal data captured in the EU portal, \nand shall be identified as such in Annex I of the Joint Controllership \nArrangement. \n\nPART 14 \nREVOCATIONS", "text_norm": "58 authority national office shall state joint controller purpose processing personal data captured eu portal shall identified annex joint controllership arrangement part 14 revocation", "start_char": 68051, "end_char": 68315, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-59", "parent_doc_id": "si-2022-0099", "section_id": "reg-59", "section_label": "Regulation 59.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "59. Subject to Regulations 61 and 62, the following are revoked:", "text_raw": "59. Subject to Regulations 61 and 62, the following are revoked: \n\n(a) European Communities (Clinical Trials on Medicinal Products \nfor Human Use) Regulations 2004 (S.I. No. 190 of 2004); \n\n(b) European Communities (Clinical Trials on Medicinal Products \nfor Human Use) (Amendment) Regulations 2004 (S.I. No. 878 of \n2004); \n\n(c) European Communities (Clinical Trials on Medicinal Products \nfor Human Use) (Amendment No. 2) Regulations 2006 (S.I. No. \n374 of 2006); \n\n(d) European Communities (Clinical Trials on Medicinal Products \nfor Human Use) (Amendment) Regulations 2009 (S.I. No. 1 of \n2009). \n\n(e) European Union (Clinical Trials on Medicinal Products for \n\nHuman Use) Regulations 2022 (S.I. No. 40 of 2022). \n\n \n \n \n \n \n \n \n \n \n\f32 [99] \n\nENTRY INTO FORCE AND TRANSITIONAL ARRANGEMENTS \n\nPART 15", "text_norm": "59 subject regulation 61 62 following revoked (a) european community (clinical trial medicinal product human use) regulation 2004 (s.i no 190 2004) (b) european community (clinical trial medicinal product human use) (amendment) regulation 2004 (s.i no 878 2004) (c) european community (clinical trial medicinal product human use) (amendment no 2) regulation 2006 (s.i no 374 2006) (d) european community (clinical trial medicinal product human use) (amendment) regulation 2009 (s.i no 1 2009) (e) european union (clinical trial medicinal product human use) regulation 2022 (s.i no 40 2022) 32 99 entry force transitional arrangement part 15", "start_char": 68315, "end_char": 69122, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-60", "parent_doc_id": "si-2022-0099", "section_id": "reg-60", "section_label": "Regulation 60.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "60. These Regulations will come into operation immediately and shall only", "text_raw": "60. These Regulations will come into operation immediately and shall only \napply to clinical trial applications submitted under the Clinical Trials Regulation.", "text_norm": "60 regulation come operation immediately shall apply clinical trial application submitted clinical trial regulation", "start_char": 69122, "end_char": 69284, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-61", "parent_doc_id": "si-2022-0099", "section_id": "reg-61", "section_label": "Regulation 61.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "61. Notwithstanding the revocation, by Regulation 59 of these Regulations", "text_raw": "61. Notwithstanding the revocation, by Regulation 59 of these Regulations \nand Regulation 37 of S.I. No. 40 of 2022, of the European Communities (Clinical \nTrials on Medicinal Products for Human Use) Regulations 2004 - \n\n(a) \n\nthose Regulations shall continue to apply until the 30th day of \nJanuary 2025 \n\n(i) \n\n(ii) \n\nin respect of an application submitted in accordance with \nthose Regulations before the 31st day of January 2022, and \nin respect of an application made on or before the 31st day \nof January 2023, where the sponsor opted to make the \napplication in accordance with those Regulations, and \n\n(b) \n\na sponsor of a clinical trial that received a favourable opinion \nfrom an ethics committee recognised by the Minister in \naccordance with Part 2 of those Regulations and, in relation to \nwhich trial the Authority granted an authorisation, shall continue \nto comply with his or her reporting obligations under those \nRegulations until the 31st day of January 2025.", "text_norm": "61 notwithstanding revocation regulation 59 regulation regulation 37 s.i no 40 2022 european community (clinical trial medicinal product human use) regulation 2004 - (a) regulation shall continue apply 30th day january 2025 (i) (ii) respect application submitted accordance regulation 31st day january 2022 respect application made 31st day january 2023 sponsor opted make application accordance regulation (b) sponsor clinical trial received favourable opinion ethic committee recognised minister accordance part 2 regulation relation trial authority granted authorisation shall continue comply reporting obligation regulation 31st day january 2025", "start_char": 69284, "end_char": 70266, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-62", "parent_doc_id": "si-2022-0099", "section_id": "reg-62", "section_label": "Regulation 62.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "62. (1) Subject to paragraph (2), any", "text_raw": "62. (1) Subject to paragraph (2), any \n\n(a) manufacturer’s licence granted under Regulation 33 of the \nEuropean Communities (Clinical Trials on Medicinal Products \nfor Human Use) Regulations 2004 (S.I. 190 of 2004), or \n\n(b) manufacturer’s authorisation granted under Regulation 8 of the \nMedicinal Products (Control of Manufacture) Regulations 2007 \nto 2019 in respect of investigational medicinal products, \n\nshall continue to be in force as if granted under these Regulations. \n\n(2) An application made in respect of the grant or variation of a \nmanufacturer’s authorisation under the Medicinal Products (Control of \nManufacture) Regulations 2007 to 2019, and which has not been determined \nprior to the date of coming into force of these Regulations, shall be considered \nas if it were an application made under Regulation 36 of these Regulations. In \nall cases, where the information provided in such applications is not sufficient, \nthe Authority may require that the applicant shall update his or her application \nto conform to the provisions of Regulation 36. \n\n(3) Persons referred to in Regulation 29 who had commenced their activity \nbefore 31 January 2022 shall submit the application to the Authority to be listed \non the Register of Exemptions by 31st March 2022. \n\n \n \n \n \n\f63. Subject to Regulations 61 and 62 of these Regulations, any action taken \nin reliance upon S.I. No. 40 of 2022 prior to the commencement of these \nRegulations and after the commencement of S.I. No. 40 of 2022 shall be deemed \nto be regulated by these Regulations. \n\n[99] 33 \n\nGIVEN under my Official Seal, \n\n2 March, 2022. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n \n \n \n\f34 [99]", "text_norm": "62 (1) subject paragraph (2) (a) manufacturer licence granted regulation 33 european community (clinical trial medicinal product human use) regulation 2004 (s.i 190 2004) (b) manufacturer authorisation granted regulation 8 medicinal product (control manufacture) regulation 2007 2019 respect investigational medicinal product shall continue force granted regulation (2) application made respect grant variation manufacturer authorisation medicinal product (control manufacture) regulation 2007 2019 determined prior date coming force regulation shall considered application made regulation 36 regulation case information provided application sufficient authority may require applicant shall update application conform provision regulation 36 (3) person referred regulation 29 commenced activity 31 january 2022 shall submit application authority listed register exemption 31st march 2022 63 subject regulation 61 62 regulation action taken reliance upon s.i no 40 2022 prior commencement regulation commencement s.i no 40 2022 shall deemed regulated regulation 99 33 given official seal 2 march 2022 stephen donnelly minister health 34 99", "start_char": 70266, "end_char": 71960, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-schedule", "parent_doc_id": "si-2022-0099", "section_id": "schedule", "section_label": "SCHEDULE", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "PROCEDURAL PROVISIONS RELATING TO DECISIONS TO REFUSE A", "text_raw": "SCHEDULE I \n\nPROCEDURAL PROVISIONS RELATING TO DECISIONS TO REFUSE A \nREQUEST FOR CLINICAL TRIAL AUTHORISATION OR TO REFUSE A \nSUBSTANTIAL MODIFICATION TO AN AUTHORISED CLINICAL \nTRIAL", "text_norm": "schedule procedural provision relating decision refuse request clinical trial authorisation refuse substantial modification authorised clinical trial", "start_char": 71960, "end_char": 72147, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-1", "parent_doc_id": "si-2022-0099", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "1. Where the Authority is notified of the sponsor's wish to appeal a decision in", "text_raw": "1. Where the Authority is notified of the sponsor's wish to appeal a decision in \naccordance with Regulation 45, the Authority shall determine if the appeal \nrelates to the conclusion on the Part I or Part II assessment, or both, and \n\n(1) in the case of an appeal relating solely to the conclusion on Part I of the \nassessment report, process the appeal in accordance with point 2; or \n\n(2) in the case of an appeal relating solely to the conclusion on Part II of \nthe assessment report, refer the appeal to the National Office for processing \nin accordance with point 3; or \n\n(3) in the case of an appeal relating to the conclusions of both Part I and \nPart II of the assessment reports, process the Part I aspects in accordance \nwith point 2, and refer the appeal to the National Office for processing of \nthe Part II aspects in accordance with point 3; \n\nand shall notify the sponsor how the appeal shall be heard.", "text_norm": "1 authority notified sponsor wish appeal decision accordance regulation 45 authority shall determine appeal relates conclusion part part ii assessment (1) case appeal relating solely conclusion part assessment report process appeal accordance point 2 (2) case appeal relating solely conclusion part ii assessment report refer appeal national office processing accordance point 3 (3) case appeal relating conclusion part part ii assessment report process part aspect accordance point 2 refer appeal national office processing part ii aspect accordance point 3 shall notify sponsor appeal shall heard", "start_char": 72147, "end_char": 73068, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-2", "parent_doc_id": "si-2022-0099", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "2. (1) The Authority shall afford an opportunity for the sponsor to make", "text_raw": "2. (1) The Authority shall afford an opportunity for the sponsor to make \nrepresentations to the Advisory Committee for Human Medicines. \n\n(2) The Advisory Committee may seek advice on ethical aspects of the \nappeal from the National Office and/or the nominated ethics committee, if \nrelevant. \n\n(3) After considering the representations, the Advisory Committee shall \nreport its findings and advice, and the reasons for its advice, to the \nAuthority. \n\n(4) The Authority shall, after considering the report of the Advisory \nCommittee – \n\n \n \n \n \n \n \n \n \n \n \n \n \n\f[99] 35 \n\n(a) confirm the administrative single decision not to accept the \nrequest for authorisation of a clinical trial application or \nsubstantial modification application, \n\n or \n\n(b) accept the request for authorisation of a clinical trial application \n\nor substantial modification application.", "text_norm": "2 (1) authority shall afford opportunity sponsor make representation advisory committee human medicine (2) advisory committee may seek advice ethical aspect appeal national office nominated ethic committee relevant (3) considering representation advisory committee shall report finding advice reason advice authority (4) authority shall considering report advisory committee - 99 35 (a) confirm administrative single decision accept request authorisation clinical trial application substantial modification application (b) accept request authorisation clinical trial application substantial modification application", "start_char": 73068, "end_char": 73934, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-3", "parent_doc_id": "si-2022-0099", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "3. (1) The National Office shall establish an appeals panel, and that panel shall", "text_raw": "3. (1) The National Office shall establish an appeals panel, and that panel shall \nhear the appeal, in accordance with Regulations 25 and 26 of S.I. No. 41 of", "text_norm": "3 (1) national office shall establish appeal panel panel shall hear appeal accordance regulation 25 26 s.i no 41", "start_char": 73934, "end_char": 74094, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-2022", "parent_doc_id": "si-2022-0099", "section_id": "reg-2022", "section_label": "Regulation 2022.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "(2) The National Office shall notify the Authority of the outcome of the", "text_raw": "2022. \n\n(2) The National Office shall notify the Authority of the outcome of the \nappeal no later than 45 days after the appeal was referred to it pursuant to \npoint (1). \n\n(3) The National Office shall, after considering the report of the appeals \npanel— \n\n(a) confirm the administrative single decision not to accept the \nrequest for authorisation of a clinical trial application or \nsubstantial modification application, or \n\n(b) accept the request for authorisation of a clinical trial application \n\nor substantial modification application.", "text_norm": "2022 (2) national office shall notify authority outcome appeal later 45 day appeal referred pursuant point (1) (3) national office shall considering report appeal panel-- (a) confirm administrative single decision accept request authorisation clinical trial application substantial modification application (b) accept request authorisation clinical trial application substantial modification application", "start_char": 74094, "end_char": 74641, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-4", "parent_doc_id": "si-2022-0099", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "4. (1) In the case of an appeal to which point 1(3) applies, the Authority shall,", "text_raw": "4. (1) In the case of an appeal to which point 1(3) applies, the Authority shall, \nafter considering the report of the Advisory Committee pursuant to point 2(3), \nand the report of the appeals panel committee pursuant to point 3(2), \n\n(a) confirm the administrative single decision not to accept the \nrequest for authorisation of a clinical trial application or \nsubstantial modification application; or \n\n(b) accept the request for authorisation of a clinical trial application \n\nor substantial modification application. \n\n(2) In the case of an appeal to which point 1(3) applies, if the appeal on one \n\naspect of the assessment report is not successful, the appeal shall not be \n\nupheld.", "text_norm": "4 (1) case appeal point 1(3) applies authority shall considering report advisory committee pursuant point 2(3) report appeal panel committee pursuant point 3(2) (a) confirm administrative single decision accept request authorisation clinical trial application substantial modification application (b) accept request authorisation clinical trial application substantial modification application (2) case appeal point 1(3) applies appeal one aspect assessment report successful appeal shall upheld", "start_char": 74641, "end_char": 75333, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-5", "parent_doc_id": "si-2022-0099", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "The Authority shall notify the sponsor of the outcome of the appeal no", "text_raw": "5. \n\nThe Authority shall notify the sponsor of the outcome of the appeal no \nlater than 52 days after receipt of the appeal. \n\n \n \n \n \n \n \n \n \n \n \n \n \n\f36 [99]", "text_norm": "5 authority shall notify sponsor outcome appeal later 52 day receipt appeal 36 99", "start_char": 75333, "end_char": 75495, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-schedule", "parent_doc_id": "si-2022-0099", "section_id": "schedule", "section_label": "SCHEDULE", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "PARTICULARS THAT MUST ACCOMPANY AN APPLICATION FOR A", "text_raw": "SCHEDULE II \n\nPARTICULARS THAT MUST ACCOMPANY AN APPLICATION FOR A \nMANUFACTURER’S AUTHORISATION", "text_norm": "schedule ii particular must accompany application manufacturer authorisation", "start_char": 75495, "end_char": 75594, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-1", "parent_doc_id": "si-2022-0099", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "1. The name and address of the natural or legal person proposed to be the", "text_raw": "1. The name and address of the natural or legal person proposed to be the \nauthorisation holder.", "text_norm": "1 name address natural legal person proposed authorisation holder", "start_char": 75594, "end_char": 75693, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-2", "parent_doc_id": "si-2022-0099", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "2. The address of each of the premises where the manufacturing or importation", "text_raw": "2. The address of each of the premises where the manufacturing or importation \nof the investigational medicinal products to which the application relates, \nincluding any testing and controls associated with such activities, that are to be \ncarried out.", "text_norm": "2 address premise manufacturing importation investigational medicinal product application relates including testing control associated activity carried out", "start_char": 75693, "end_char": 75948, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-3", "parent_doc_id": "si-2022-0099", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "3. The name of any organisation and address of the associated premises to which", "text_raw": "3. The name of any organisation and address of the associated premises to which \nthe proposed authorisation holder proposes to outsource manufacturing, testing \nactivities concerning the investigational medicinal product.", "text_norm": "3 name organisation address associated premise proposed authorisation holder proposes outsource manufacturing testing activity concerning investigational medicinal product", "start_char": 75948, "end_char": 76172, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-4", "parent_doc_id": "si-2022-0099", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "4. (1) A site master file covering the premises, manufacturing, importation and", "text_raw": "4. (1) A site master file covering the premises, manufacturing, importation and \n\nquality control operations specified in the application form. \n\n(2) A site master file shall be prepared in accordance with the guidance \npublished by the European Commission in Part III of the EU Good \nManufacturing Practice guidelines.", "text_norm": "4 (1) site master file covering premise manufacturing importation quality control operation specified application form (2) site master file shall prepared accordance guidance published european commission part iii eu good manufacturing practice guideline", "start_char": 76172, "end_char": 76494, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-5", "parent_doc_id": "si-2022-0099", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "5. (1) The name, qualifications and experience of the qualified person who shall", "text_raw": "5. (1) The name, qualifications and experience of the qualified person who shall \ncarry out the duties referred to in Article 62 of the Clinical Trials Regulation. \n\n(2) In the case of an authorisation relating to manufacturing activities, the \nname, qualification and experience of the production manager other person \nwhose duty it shall be to supervise the production operations at each of the \npremises referred to in point 2. \n\n(3) In the case of an authorisation relating to manufacturing activities, that \nname and degrees, diplomas or other qualifications and experience of the \nperson to be in charge of quality control over all the premises referred to in \npoint 2.", "text_norm": "5 (1) name qualification experience qualified person shall carry duty referred article 62 clinical trial regulation (2) case authorisation relating manufacturing activity name qualification experience production manager person whose duty shall supervise production operation premise referred point 2 (3) case authorisation relating manufacturing activity name degree diploma qualification experience person charge quality control premise referred point 2", "start_char": 76494, "end_char": 77172, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-6", "parent_doc_id": "si-2022-0099", "section_id": "reg-6", "section_label": "Regulation 6.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "6. In this Schedule, the reference to investigational medicinal products includes", "text_raw": "6. In this Schedule, the reference to investigational medicinal products includes \nblood products, immunological products, cell therapy products, gene therapy \nproducts, biotechnology products, human or animal extracted products, herbal \nproducts, homeopathic products, radiopharmaceutical products and products \ncontaining chemical agents. \n\n \n \n \n \n \n \n \n \n\f[99] 37", "text_norm": "6 schedule reference investigational medicinal product includes blood product immunological product cell therapy product gene therapy product biotechnology product human animal extracted product herbal product homeopathic product radiopharmaceutical product product containing chemical agent 99 37", "start_char": 77172, "end_char": 77542, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-schedule", "parent_doc_id": "si-2022-0099", "section_id": "schedule", "section_label": "SCHEDULE", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "PROCEDURAL PROVISIONS RELATING TO PROPOSALS TO GRANT", "text_raw": "SCHEDULE III \n\nPROCEDURAL PROVISIONS RELATING TO PROPOSALS TO GRANT \nSUBJECT TO THE CARRYING OUT OF CERTAIN OBLIGATIONS, \nPROPOSALS TO GRANT OTHERWISE THAN IN ACCORDANCE WITH \nTHE APPLICATION, PROPOSALS TO REFUSE TO GRANT OR VARY, \nPROPOSALS TO MAKE THE AUTHORISATION CONDITIONAL ON \nTHE CARRYING OUT OF CERTAIN OBLIGATIONS, AND PROPOSALS \nTO SUSPEND, VARY OR REVOKE A MANUFACTURER’S \nAUTHORISATION", "text_norm": "schedule iii procedural provision relating proposal grant subject carrying certain obligation proposal grant otherwise accordance application proposal refuse grant vary proposal make authorisation conditional carrying certain obligation proposal suspend vary revoke manufacturer authorisation", "start_char": 77542, "end_char": 77943, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-1", "parent_doc_id": "si-2022-0099", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "1. In this Schedule—", "text_raw": "1. In this Schedule— \n\n‘authorisation’ means a manufacturer’s authorisation, and \n\n‘time allowed’ means the period of 28 days or such extended period as the \nAuthority may in any particular case allow.", "text_norm": "1 schedule-- authorisation mean manufacturer authorisation time allowed mean period 28 day extended period authority may particular case allow", "start_char": 77943, "end_char": 78147, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-2", "parent_doc_id": "si-2022-0099", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "2. Subject to point 6, if the Authority proposes—", "text_raw": "2. Subject to point 6, if the Authority proposes— \n\n(1) not to grant an authorisation, \n\n(2) to grant an authorisation subject to the carrying out of certain \nobligations, \n\n(3) to grant an authorisation other than in accordance with the application, \n\n(4) to revoke, vary or suspend an authorisation, \n\n(5) not to vary an authorisation on the holder’s application to vary, or \n\n(6) to make an authorisation conditional on the carrying out of certain \nobligations, \n\nthe Authority shall notify the applicant or authorisation holder accordingly.", "text_norm": "2 subject point 6 authority proposes-- (1) grant authorisation (2) grant authorisation subject carrying certain obligation (3) grant authorisation accordance application (4) revoke vary suspend authorisation (5) vary authorisation holder application vary (6) make authorisation conditional carrying certain obligation authority shall notify applicant authorisation holder accordingly", "start_char": 78147, "end_char": 78694, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-3", "parent_doc_id": "si-2022-0099", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "3. Any notification given under point 2 shall include—", "text_raw": "3. Any notification given under point 2 shall include— \n\n(1) a statement of the proposals of the Authority, \n\n(2) a statement setting out in detail the reasons on which the said proposals \n\nare based, and \n\n(3) a statement that the applicant or authorisation holder has the right to \nmake representations to the Authority in response to the notification.", "text_norm": "3 notification given point 2 shall include-- (1) statement proposal authority (2) statement setting detail reason said proposal based (3) statement applicant authorisation holder right make representation authority response notification", "start_char": 78694, "end_char": 79051, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-4", "parent_doc_id": "si-2022-0099", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "4. A person to whom notification has been given under point 2 may, within the", "text_raw": "4. A person to whom notification has been given under point 2 may, within the \ntime allowed after the notification was given, give notice to the Authority of \nhis or her wish to do so, and make representations to the Authority with \nrespect to the decision or proposal referred to in the notification.", "text_norm": "4 person notification given point 2 may within time allowed notification given give notice authority wish make representation authority respect decision proposal referred notification", "start_char": 79051, "end_char": 79355, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-5", "parent_doc_id": "si-2022-0099", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "5. The Authority shall, after considering the representations, decide whether to", "text_raw": "5. The Authority shall, after considering the representations, decide whether to \ngrant the authorisation, revoke, vary or suspend an authorisation or confirm \nor alter its decision, as the case may be. \n\n \n \n \n \n \n \n \n \n \n\f38 [99]", "text_norm": "5 authority shall considering representation decide whether grant authorisation revoke vary suspend authorisation confirm alter decision case may be 38 99", "start_char": 79355, "end_char": 79589, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-6", "parent_doc_id": "si-2022-0099", "section_id": "reg-6", "section_label": "Regulation 6.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "6. (1) Point 2 shall not apply to the suspension of an authorisation where it", "text_raw": "6. (1) Point 2 shall not apply to the suspension of an authorisation where it \nappears to the Authority that, in the interests of safety, it is necessary to \nsuspend the authorisation with immediate effect for a period not exceeding 3 \nmonths. \n\n(2) If, after the aforementioned suspension has taken effect, it appears to the \nAuthority that the authorisation should be further suspended or revoked, \nthe Authority shall proceed in accordance with the provisions of points 2 \nto 5. \n\n \n\f[99] 39", "text_norm": "6 (1) point 2 shall apply suspension authorisation appears authority interest safety necessary suspend authorisation immediate effect period exceeding 3 month (2) aforementioned suspension taken effect appears authority authorisation suspended revoked authority shall proceed accordance provision point 2 5 99 39", "start_char": 79589, "end_char": 80086, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-schedule", "parent_doc_id": "si-2022-0099", "section_id": "schedule", "section_label": "SCHEDULE", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "REQUIREMENTS TO BE MET BY AN AUTHORISATION HOLDER", "text_raw": "SCHEDULE IV \n\nREQUIREMENTS TO BE MET BY AN AUTHORISATION HOLDER \nMANUFACTURING OR IMPORTING INVESTIGATIONAL MEDICINAL \nPRODUCTS", "text_norm": "schedule iv requirement met authorisation holder manufacturing importing investigational medicinal product", "start_char": 80086, "end_char": 80216, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-1", "parent_doc_id": "si-2022-0099", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "1. The authorisation holder shall—", "text_raw": "1. The authorisation holder shall— \n\n(1) comply with the requirements set out in the Commission Delegated \nRegulation 2017/1569, \n\n(2) operate only within the scope and terms defined in the authorisation.", "text_norm": "1 authorisation holder shall-- (1) comply requirement set commission delegated regulation 2017 1569 (2) operate within scope term defined authorisation", "start_char": 80216, "end_char": 80423, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-2", "parent_doc_id": "si-2022-0099", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "2. The authorisation holder shall at all times provide and maintain such staff,", "text_raw": "2. The authorisation holder shall at all times provide and maintain such staff, \npremises equipment and facilities as will enable the qualified person at his \nor her disposal pursuant to Article 61(2)(b) of the Clinical Trials \nRegulation to carry out the duties referred to in Article 62(1) of the Clinical \nTrials Regulation.", "text_norm": "2 authorisation holder shall time provide maintain staff premise equipment facility enable qualified person disposal pursuant article 61(2)(b) clinical trial regulation carry duty referred article 62(1) clinical trial regulation", "start_char": 80423, "end_char": 80753, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-3", "parent_doc_id": "si-2022-0099", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "3. The authorisation holder shall give prior written notice to the Authority—", "text_raw": "3. The authorisation holder shall give prior written notice to the Authority— \n\n(1) of any changes he or she may wish to make to any details specified \n\nin the authorisation, \n\n(2) where it is intended to introduce significant changes to the premises \nor activities to which the authorisation relates, including changes \nwhich introduce significant new risks that have to be managed.", "text_norm": "3 authorisation holder shall give prior written notice authority-- (1) change may wish make detail specified authorisation (2) intended introduce significant change premise activity authorisation relates including change introduce significant new risk managed", "start_char": 80753, "end_char": 81139, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-4", "parent_doc_id": "si-2022-0099", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "4. The authorisation holder shall, where manufacture is carried out under the", "text_raw": "4. The authorisation holder shall, where manufacture is carried out under the \nauthorisation, keep an adequate sample of each batch and of each active \nconstituent used in the manufacture of the investigational medicinal products \nto which the authorisation relates, for the period which ends one year after the \nlabelled expiry date of the product, and shall furnish on request by the \nAuthority a sufficient sample of each such batch for the purpose of any test, \nexamination or analysis which may be requested by the Authority. The \nAuthority will not be charged for any such samples.", "text_norm": "4 authorisation holder shall manufacture carried authorisation keep adequate sample batch active constituent used manufacture investigational medicinal product authorisation relates period end one year labelled expiry date product shall furnish request authority sufficient sample batch purpose test examination analysis may requested authority authority charged sample", "start_char": 81139, "end_char": 81729, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-5", "parent_doc_id": "si-2022-0099", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "5. The authorisation holder shall, where manufacture is carried out under the", "text_raw": "5. The authorisation holder shall, where manufacture is carried out under the \nauthorisation, ensure that any human blood or blood component imported into \nthe State and used by him or her as a starting material or as a raw material in \nthe manufacture of an investigational medicinal product shall meet the \nequivalent standards of quality and safety to those laid down in Commission \nDirective 2004/33/EC6.", "text_norm": "5 authorisation holder shall manufacture carried authorisation ensure human blood blood component imported state used starting material raw material manufacture investigational medicinal product shall meet equivalent standard quality safety laid commission directive 2004 33 ec6", "start_char": 81729, "end_char": 82140, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-6", "parent_doc_id": "si-2022-0099", "section_id": "reg-6", "section_label": "Regulation 6.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "6. The authorisation holder shall supply such information as may be requested", "text_raw": "6. The authorisation holder shall supply such information as may be requested \nby the Authority for the purposes of these Regulations about the \nmanufactured or imported investigational medicinal products and about the \noperations being carried out under the authorisation.", "text_norm": "6 authorisation holder shall supply information may requested authority purpose regulation manufactured imported investigational medicinal product operation carried authorisation", "start_char": 82140, "end_char": 82416, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-7", "parent_doc_id": "si-2022-0099", "section_id": "reg-7", "section_label": "Regulation 7.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "7. The authorisation holder shall for the purpose of enabling the Authority to—", "text_raw": "7. The authorisation holder shall for the purpose of enabling the Authority to— \n\n6 O.J. No. L 91, 30.3.2004, p. 25. \n\n \n \n \n \n \n \n \n\f40 [99] \n\n(1) verify any statement contained in an application for a manufacturer’s \nauthorisation or clinical trial application, or \n\n(2) ascertain whether there are any grounds for suspending, revoking or \namending any such authorisation, \n\npermit, and provide all necessary facilities to enable, authorised officers to \nenter and inspect his or her premises at any time and to take such samples or \nto take copies of any documents in relation to any such application or \nauthorisation as may be required.", "text_norm": "7 authorisation holder shall purpose enabling authority to-- 6 o.j no l 91 30.3.2004 p 25 40 99 (1) verify statement contained application manufacturer authorisation clinical trial application (2) ascertain whether ground suspending revoking amending authorisation permit provide necessary facility enable authorised officer enter inspect premise time take sample take copy document relation application authorisation may required", "start_char": 82416, "end_char": 83060, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-8", "parent_doc_id": "si-2022-0099", "section_id": "reg-8", "section_label": "Regulation 8.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "8. The authorisation holder shall from time to timer permit such inspection and", "text_raw": "8. The authorisation holder shall from time to timer permit such inspection and \nmake available such information as may be required to satisfy the Authority \nthat the conditions of the authorisation are being complied with.", "text_norm": "8 authorisation holder shall time timer permit inspection make available information may required satisfy authority condition authorisation complied with", "start_char": 83060, "end_char": 83286, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-9", "parent_doc_id": "si-2022-0099", "section_id": "reg-9", "section_label": "Regulation 9.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "9. Where the authorisation holder has been informed by the Authority that any", "text_raw": "9. Where the authorisation holder has been informed by the Authority that any \npart of a batch of an investigational medicinal product to which his or her \nauthorisation relates has been found not to conform as regards strength, \nquality or purity with the specifications of the relevant investigational \nmedicinal product he or she shall, if so directed by the Authority, immediately \nwithhold the remainder of that batch from sale, supply or exportation and, \ninsofar as may be practicable, immediately recall all supplies already sold, \nsupplied or exported from that batch.", "text_norm": "9 authorisation holder informed authority part batch investigational medicinal product authorisation relates found conform regard strength quality purity specification relevant investigational medicinal product shall directed authority immediately withhold remainder batch sale supply exportation insofar may practicable immediately recall supply already sold supplied exported batch", "start_char": 83286, "end_char": 83866, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-10", "parent_doc_id": "si-2022-0099", "section_id": "reg-10", "section_label": "Regulation 10.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "10. Where the authorisation holder has been informed by the Authority that an", "text_raw": "10. Where the authorisation holder has been informed by the Authority that an \ninvestigational medicinal product to which his or her authorisation relates has \nbeen found to give rise to concerns in regard to its safety or efficacy, he or \nshe shall, if so directed by the Authority, immediately withhold that \ninvestigational medicinal product from sale, supply or exportation and, \ninsofar as may be practicable, immediately recall all supplies of such \ninvestigational medicinal product already sold, supplied or exported.", "text_norm": "10 authorisation holder informed authority investigational medicinal product authorisation relates found give rise concern regard safety efficacy shall directed authority immediately withhold investigational medicinal product sale supply exportation insofar may practicable immediately recall supply investigational medicinal product already sold supplied exported", "start_char": 83866, "end_char": 84394, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-11", "parent_doc_id": "si-2022-0099", "section_id": "reg-11", "section_label": "Regulation 11.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "11. Where the authorisation holder has been informed by the Authority that any", "text_raw": "11. Where the authorisation holder has been informed by the Authority that any \nbatch of an investigational medicinal product, or part thereof, to which his or \nher authorisation relates, has not been manufactured in accordance with the \nprinciples and guidelines of good manufacturing practice set out in the \nCommission Delegated Regulation 2017/1569, he or she shall, if so requested \nby the Authority, immediately withhold that investigational medicinal \nproduct from sale, supply or exportation and, insofar as may be practicable, \nimmediately recall all supplies of such investigational medicinal product \nalready sold, supplied or exported.", "text_norm": "11 authorisation holder informed authority batch investigational medicinal product part thereof authorisation relates manufactured accordance principle guideline good manufacturing practice set commission delegated regulation 2017 1569 shall requested authority immediately withhold investigational medicinal product sale supply exportation insofar may practicable immediately recall supply investigational medicinal product already sold supplied exported", "start_char": 84394, "end_char": 85044, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-12", "parent_doc_id": "si-2022-0099", "section_id": "reg-12", "section_label": "Regulation 12.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "12. Where the authorisation holder decides for whatever reason to recall a", "text_raw": "12. Where the authorisation holder decides for whatever reason to recall a \nparticular batch of an investigational medicinal product manufactured or \nimported by him or her, or part thereof, he or she shall forthwith inform the \nAuthority of the decision to recall and of the reason for such recall.", "text_norm": "12 authorisation holder decides whatever reason recall particular batch investigational medicinal product manufactured imported part thereof shall forthwith inform authority decision recall reason recall", "start_char": 85044, "end_char": 85346, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-13", "parent_doc_id": "si-2022-0099", "section_id": "reg-13", "section_label": "Regulation 13.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "13. Where the authorisation holder considers that there may be grounds for the", "text_raw": "13. Where the authorisation holder considers that there may be grounds for the \nrecall, or for the imposition of an abnormal restriction on the supply of a \nparticular investigational medicinal product manufactured or imported by \nhim or her, or of a batch or part of batch thereof, he or she shall consult with \nthe Authority in relation to the action which may be considered appropriate \nin the circumstances. \n\n \n\f[99] 41", "text_norm": "13 authorisation holder considers may ground recall imposition abnormal restriction supply particular investigational medicinal product manufactured imported batch part batch thereof shall consult authority relation action may considered appropriate circumstance 99 41", "start_char": 85346, "end_char": 85773, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-14", "parent_doc_id": "si-2022-0099", "section_id": "reg-14", "section_label": "Regulation 14.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "14. (1) The authorisation holder, in the case of manufacture of an advanced", "text_raw": "14. (1) The authorisation holder, in the case of manufacture of an advanced \ntherapy investigational medicinal product, shall establish and maintain a \nsystem ensuring that the individual product and its starting and raw \nmaterials, including all substances coming into contact with the cells or \ntissues it may contain, can be traced through the sourcing, manufacturing, \npackaging, storage, transport and delivery to the trial site where the \nproduct is used. \n\n(2) Where an authorisation holder manufactures an advanced therapy \ninvestigational medicinal product that contains human cells or tissues, he \nor she shall ensure that the traceability systems established in accordance \nwith subparagraph 1 are complimentary to, and compatible with, the \nrequirements laid down in Articles 8 and 14 of Directive 2004/23/EC7, \nand Articles 14 and 24 of Directive 2002/98/EC8. \n\n(3) The authorisation holder shall keep the data referred to in paragraph (1) \n\nfor a minimum of 30 years after the expiry date of the product. \n\n(4) In the case of bankruptcy or liquidation of the authorisation holder who \nhas manufactured an advanced therapy investigational medicinal \nproduct, and in the event that the manufacturer’s authorisation is not \ntransferred to another legal entity, the data referred to in paragraph (1) \nshall be transferred to the Authority. \n\n(5) In the event that the manufacturer’s authorisation is suspended, revoked \nor withdrawn, the holder of the manufacturer’s authorisation shall remain \nsubject to the obligations laid down in paragraphs (1), (2) and (3). \n\n(6) Paragraphs (3) to (5) shall not apply to a holder of a manufacturer’s \nauthorisation where the holder of a marketing authorisation for the \nrelevant advanced therapy investigational medicinal product is, by virtue \nof such marketing authorisation, responsible for the retention of such \ndata.", "text_norm": "14 (1) authorisation holder case manufacture advanced therapy investigational medicinal product shall establish maintain system ensuring individual product starting raw material including substance coming contact cell tissue may contain traced sourcing manufacturing packaging storage transport delivery trial site product used (2) authorisation holder manufacture advanced therapy investigational medicinal product contains human cell tissue shall ensure traceability system established accordance subparagraph 1 complimentary compatible requirement laid article 8 14 directive 2004 23 ec7 article 14 24 directive 2002 98 ec8 (3) authorisation holder shall keep data referred paragraph (1) minimum 30 year expiry date product (4) case bankruptcy liquidation authorisation holder manufactured advanced therapy investigational medicinal product event manufacturer authorisation transferred another legal entity data referred paragraph (1) shall transferred authority (5) event manufacturer authorisation suspended revoked withdrawn holder manufacturer authorisation shall remain subject obligation laid paragraph (1) (2) (3) (6) paragraph (3) (5) shall apply holder manufacturer authorisation holder marketing authorisation relevant advanced therapy investigational medicinal product virtue marketing authorisation responsible retention data", "start_char": 85773, "end_char": 87648, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-15", "parent_doc_id": "si-2022-0099", "section_id": "reg-15", "section_label": "Regulation 15.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "15. The content of the site master file shall be kept up to date at all times. Each", "text_raw": "15. The content of the site master file shall be kept up to date at all times. Each \ntime the site master file is updated, a copy of the updated file shall be provided \nto the Authority.", "text_norm": "15 content site master file shall kept date time time site master file updated copy updated file shall provided authority", "start_char": 87648, "end_char": 87837, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-reg-16", "parent_doc_id": "si-2022-0099", "section_id": "reg-16", "section_label": "Regulation 16.", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "16. The Authority may request the authorisation holder to confirm accuracy of", "text_raw": "16. The Authority may request the authorisation holder to confirm accuracy of \n\ndetails within the site master file. \n\n7 O.J. No. L 102, 7.4.2004, p. 48. \n8 O.J. No. L 33, 8.2.2003, p. 30. \n\n \n \n \n \n\f42 [99]", "text_norm": "16 authority may request authorisation holder confirm accuracy detail within site master file 7 o.j no l 102 7.4.2004 p 48 8 o.j no l 33 8.2.2003 p 30 42 99", "start_char": 87837, "end_char": 88047, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
{"doc_id": "si-2022-0099-explanatory-note", "parent_doc_id": "si-2022-0099", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 99 of 2022", "title": "2. (1) These Regulations apply to all clinical trials conducted in the State.", "year": 2022, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation). \n\nThese Regulations give further effect to Regulation (EC) No. 536/2014 of the \nEuropean Parliament and of the Council of 16 April 2014 on clinical trials on \nmedicinal products for human use (“Clinical Trials Regulation”) which applied \nfrom the 31st of January 2022. \n\nThe Clinical Trials Regulation replaces and repeals Directive 2001/20/EC on the \napproximation of the laws, regulations and administrative provisions of the \nMember States relating to the implementation of good clinical practice in the \nconduct of clinical trials on medicinal products for human use. \n\nThe National Office and National Research Ethics Committees, have been \ndefined in separate Regulations, the European Union Clinical Trials on \nMedicinal Products for Human Use) (National Research Ethics Committees) \nRegulations 2022 (S.I. No. 41 of 2022). \n\nThese Regulations also revoke S.I. No. 40 of 2022, which was put in place as \ninterim regulations to transpose those elements of the Clinical Trials Regulation \nwhich concerned Member State competences into Irish Law from the date of the \napplication of the Clinical Trials Regulation. These regulations now replace S.I. \nNo. 40 of 2022 as the Principal Regulations which give further effect to the \nClinical Trials Regulation. \n\n \n \n \n \n \n \n \n \n \n\f[99] 43 \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€ 8.00 \n\n(DH-386) 75. 3/22. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation) regulation give effect regulation (ec) no 536 2014 european parliament council 16 april 2014 clinical trial medicinal product human use ( clinical trial regulation ) applied 31st january 2022 clinical trial regulation replaces repeal directive 2001 20 ec approximation law regulation administrative provision member state relating implementation good clinical practice conduct clinical trial medicinal product human use national office national research ethic committee defined separate regulation european union clinical trial medicinal product human use) (national research ethic committees) regulation 2022 (s.i no 41 2022) regulation also revoke s.i no 40 2022 put place interim regulation transpose element clinical trial regulation concerned member state competence irish law date application clinical trial regulation regulation replace s.i no 40 2022 principal regulation give effect clinical trial regulation 99 43 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur 8.00 (dh-386) 75 3 22 propylon", "start_char": 88047, "end_char": 89935, "source_path": "downloads\\2022\\2022_0098.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d2840a701048b72102019cbebf937348d3c6198b492cfa2d9102a02d03cf09bd", "cross_refs": []}
